1
|
Morelli L, Ochoa E, Salvioni L, Davide Giustra M, De Santes B, Spena F, Barbieri L, Garbujo S, Tomaino G, Novati B, Bolis L, Moutaharrik S, Prosperi D, Palugan L, Colombo M. Microfluidic nanoparticle synthesis for oral solid dosage forms: A step toward clinical transition processes. Int J Pharm 2024; 652:123850. [PMID: 38280498 DOI: 10.1016/j.ijpharm.2024.123850] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2023] [Revised: 01/11/2024] [Accepted: 01/21/2024] [Indexed: 01/29/2024]
Abstract
Nanomedicine provides various opportunities for addressing medical challenges associated with drug bioavailability, stability, and efficacy. In particular, oral nanoparticles (NPs) represent an alternative strategy to enhance the solubility and stability of active ingredients through the gastrointestinal tract. The nanocarriers could be used for both local and systemic targeting, enabling controlled release of encapsulated drugs. This approach allows more efficient therapies. In this work, we aim to develop reliable oral solid dosage forms incorporating NPs produced by either one pot synthesis or continuous production, following protocols that yield highly consistent outcomes, promoting their technology transfer and clinical use. Microfluidics technology was selected to allow an automated and highly productive synthetic approach suitable for the highly throughput production. In particular, innovative systems, which combine advantage of NPs and solid dosage formulation, were designed, developed, and characterized demonstrating the possibility to obtaining oral administration. The resulting NPs were thus carried on oral dosage forms, i.e., pellets and minitablets. NPs resulted stable after dosage forms manufacturing, leading to confidence also on protection of encapsulated drugs. Indomethacin was used as a tracer to test biopharmaceutical behaviour. Anti-inflammatories or cytotoxic chemotherapeutics could be vehiculated leading to a breakthrough in the treatment of severe diseases allowing the oral administration of these drugs. We believe that the advancement achieved with the results of our work paves the way for the progression of nanoproducts into clinical transition processes.
Collapse
Affiliation(s)
- Lucia Morelli
- University of Milano-Bicocca, Department of Biotechnology and Bioscience, Piazza della Scienza 2, 20126 Milano, Italy
| | - Evelyn Ochoa
- University of Milano-Bicocca, Department of Biotechnology and Bioscience, Piazza della Scienza 2, 20126 Milano, Italy
| | - Lucia Salvioni
- University of Milano-Bicocca, Department of Biotechnology and Bioscience, Piazza della Scienza 2, 20126 Milano, Italy
| | - Marco Davide Giustra
- University of Milano-Bicocca, Department of Biotechnology and Bioscience, Piazza della Scienza 2, 20126 Milano, Italy
| | - Beatrice De Santes
- University of Milano-Bicocca, Department of Biotechnology and Bioscience, Piazza della Scienza 2, 20126 Milano, Italy
| | - Francesca Spena
- University of Milano-Bicocca, Department of Biotechnology and Bioscience, Piazza della Scienza 2, 20126 Milano, Italy
| | - Linda Barbieri
- University of Milano-Bicocca, Department of Biotechnology and Bioscience, Piazza della Scienza 2, 20126 Milano, Italy
| | - Stefania Garbujo
- University of Milano-Bicocca, Department of Biotechnology and Bioscience, Piazza della Scienza 2, 20126 Milano, Italy
| | - Giulia Tomaino
- University of Milano-Bicocca, Department of Biotechnology and Bioscience, Piazza della Scienza 2, 20126 Milano, Italy
| | - Brian Novati
- University of Milano-Bicocca, Department of Biotechnology and Bioscience, Piazza della Scienza 2, 20126 Milano, Italy
| | - Leonardo Bolis
- University of Milano-Bicocca, Department of Biotechnology and Bioscience, Piazza della Scienza 2, 20126 Milano, Italy
| | - Saliha Moutaharrik
- University of Milano, Department of Pharmaceutical Sciences, Via G. Colombo 71, 20133 Milano, Italy
| | - Davide Prosperi
- University of Milano-Bicocca, Department of Biotechnology and Bioscience, Piazza della Scienza 2, 20126 Milano, Italy
| | - Luca Palugan
- University of Milano, Department of Pharmaceutical Sciences, Via G. Colombo 71, 20133 Milano, Italy.
| | - Miriam Colombo
- University of Milano-Bicocca, Department of Biotechnology and Bioscience, Piazza della Scienza 2, 20126 Milano, Italy.
| |
Collapse
|
2
|
Ochoa E, Morelli L, Salvioni L, Giustra M, De Santes B, Spena F, Barbieri L, Garbujo S, Viganò M, Novati B, Tomaino G, Moutaharrik S, Prosperi D, Palugan L, Colombo M. Co-processed materials testing as excipients to produce Orally Disintegrating Tablets (ODT) using binder jet 3D-printing technology. Eur J Pharm Biopharm 2024; 194:85-94. [PMID: 38048887 DOI: 10.1016/j.ejpb.2023.11.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2023] [Revised: 11/24/2023] [Accepted: 11/27/2023] [Indexed: 12/06/2023]
Abstract
The use of co-processed materials for Orally Disintegrating Tablets (ODT) preparation by direct compression is well consolidated. However, the evaluation of their potential for ODT preparation by 3D printing technology remains almost unexplored. The present study aimed to estimate the use of commercially available co-processed excipients, conventionally applied in compression protocols, for the preparation of ODTs with binder jetting-3D printing technology. The latter was selected among the 3D printing techniques because the deposition of multiple powder layers allows for obtaining highly porous and easily disintegrating dosage forms. The influence of some process parameters, including layer thickness, type of waveform and spread speed, on the physical and mechanical properties of the prototypes printed were evaluated. Our results suggested that binder jetting-3D printing technology could benefit from the co-processed excipients for the preparation of solid dosage forms. The process optimization conducted with the experiments reported in this work indicated that additional excipients were needed to improve the physical properties of the resulting ODTs.
Collapse
Affiliation(s)
- Evelyn Ochoa
- University of Milano-Bicocca, Department of Biotechnology and Bioscience, Piazza della Scienza 2, 20126 Milano, Italy
| | - Lucia Morelli
- University of Milano-Bicocca, Department of Biotechnology and Bioscience, Piazza della Scienza 2, 20126 Milano, Italy
| | - Lucia Salvioni
- University of Milano-Bicocca, Department of Biotechnology and Bioscience, Piazza della Scienza 2, 20126 Milano, Italy
| | - Marco Giustra
- University of Milano-Bicocca, Department of Biotechnology and Bioscience, Piazza della Scienza 2, 20126 Milano, Italy
| | - Beatrice De Santes
- University of Milano-Bicocca, Department of Biotechnology and Bioscience, Piazza della Scienza 2, 20126 Milano, Italy
| | - Francesca Spena
- University of Milano-Bicocca, Department of Biotechnology and Bioscience, Piazza della Scienza 2, 20126 Milano, Italy
| | - Linda Barbieri
- University of Milano-Bicocca, Department of Biotechnology and Bioscience, Piazza della Scienza 2, 20126 Milano, Italy
| | - Stefania Garbujo
- University of Milano-Bicocca, Department of Biotechnology and Bioscience, Piazza della Scienza 2, 20126 Milano, Italy
| | - Matteo Viganò
- University of Milano-Bicocca, Department of Biotechnology and Bioscience, Piazza della Scienza 2, 20126 Milano, Italy
| | - Brian Novati
- University of Milano-Bicocca, Department of Biotechnology and Bioscience, Piazza della Scienza 2, 20126 Milano, Italy
| | - Giulia Tomaino
- University of Milano-Bicocca, Department of Biotechnology and Bioscience, Piazza della Scienza 2, 20126 Milano, Italy
| | - Saliha Moutaharrik
- University of Milano, Department of Pharmaceutical Science, Via Colombo, 71, 20133 Milano, Italy
| | - Davide Prosperi
- University of Milano-Bicocca, Department of Biotechnology and Bioscience, Piazza della Scienza 2, 20126 Milano, Italy
| | - Luca Palugan
- University of Milano, Department of Pharmaceutical Science, Via Colombo, 71, 20133 Milano, Italy.
| | - Miriam Colombo
- University of Milano-Bicocca, Department of Biotechnology and Bioscience, Piazza della Scienza 2, 20126 Milano, Italy.
| |
Collapse
|
3
|
Sevieri M, Mazzucchelli S, Barbieri L, Garbujo S, Carelli S, Bonizzi A, Rey F, Recordati C, Recchia M, Allevi R, Sitia L, Morasso C, Zerbi P, Prosperi D, Corsi F, Truffi M. Ferritin nanoconjugates guide trastuzumab brain delivery to promote an antitumor response in murine HER2 + breast cancer brain metastasis. Pharmacol Res 2023; 196:106934. [PMID: 37734460 DOI: 10.1016/j.phrs.2023.106934] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/23/2023] [Revised: 08/31/2023] [Accepted: 09/18/2023] [Indexed: 09/23/2023]
Abstract
Brain metastasis (BM) represents a clinical challenge for patients with advanced HER2 + breast cancer (BC). The monoclonal anti-HER2 antibody trastuzumab (TZ) improves survival of BC patients, but it has low central nervous system penetrance, being ineffective in treating BM. Previous studies showed that ferritin nanoparticles (HFn) may cross the blood brain barrier (BBB) through binding to the transferrin receptor 1 (TfR1). However, whether this has efficacy in promoting the trans-BBB delivery of TZ and combating BC BM was not studied yet. Here, we investigated the potential of HFn to drive TZ brain delivery and promote a targeted antitumor response in a murine model of BC BM established by stereotaxic injection of engineered BC cells overexpressing human HER2. HFn were covalently conjugated with TZ to obtain a nanoconjugate endowed with HER2 and TfR1 targeting specificity (H-TZ). H-TZ efficiently achieved TZ brain delivery upon intraperitoneal injection and triggered stable targeting of cancer cells. Treatment with H-TZ plus docetaxel significantly reduced tumor growth and shaped a protective brain microenvironment by engaging macrophage activation toward cancer cells. H-TZ-based treatment also avoided TZ-associated cardiotoxicity by preventing drug accumulation in the heart and did not induce any other major side effects when combined with docetaxel. These results provided in vivo demonstration of the pharmacological potential of H-TZ, able to tackle BC BM in combination with docetaxel. Indeed, upon systemic administration, the nanoconjugate guides TZ brain accumulation, reduces BM growth and limits side effects in off-target organs, thus showing promise for the management of HER2 + BC metastatic to the brain.
Collapse
Affiliation(s)
- Marta Sevieri
- Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, via G.B. Grassi 74, 20157 Milan, Italy
| | - Serena Mazzucchelli
- Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, via G.B. Grassi 74, 20157 Milan, Italy
| | - Linda Barbieri
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, P.zza della Scienza 2, 20126 Milano, Italy
| | - Stefania Garbujo
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, P.zza della Scienza 2, 20126 Milano, Italy
| | - Stephana Carelli
- Pediatric Clinical Research Center "Romeo ed Enrica Invernizzi", Department of Biomedical and Clinical Science, University of Milan, 20157 Milan, Italy; Center of Functional Genomics and Rare Diseases, Department of Pediatrics, Buzzi Children's Hospital, Milano, Italy
| | - Arianna Bonizzi
- Istituti Clinici Scientifici Maugeri IRCCS, via Maugeri 4, 27100 Pavia, Italy
| | - Federica Rey
- Pediatric Clinical Research Center "Romeo ed Enrica Invernizzi", Department of Biomedical and Clinical Science, University of Milan, 20157 Milan, Italy; Center of Functional Genomics and Rare Diseases, Department of Pediatrics, Buzzi Children's Hospital, Milano, Italy
| | - Camilla Recordati
- Mouse and Animal Pathology Laboratory, Fondazione Unimi, viale Ortles 22/4, 20139 Milano, Italy; Dipartimento di Medicina Veterinaria e Scienze Animali, Università di Milano, via dell'Università 6, 26900 Lodi, Italy
| | - Matteo Recchia
- Mouse and Animal Pathology Laboratory, Fondazione Unimi, viale Ortles 22/4, 20139 Milano, Italy; Dipartimento di Medicina Veterinaria e Scienze Animali, Università di Milano, via dell'Università 6, 26900 Lodi, Italy
| | - Raffaele Allevi
- Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, via G.B. Grassi 74, 20157 Milan, Italy
| | - Leopoldo Sitia
- Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, via G.B. Grassi 74, 20157 Milan, Italy
| | - Carlo Morasso
- Istituti Clinici Scientifici Maugeri IRCCS, via Maugeri 4, 27100 Pavia, Italy
| | - Pietro Zerbi
- Anatomia Patologica, ASST Santi Paolo e Carlo, via Pio II, 3, Milano, Italy
| | - Davide Prosperi
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, P.zza della Scienza 2, 20126 Milano, Italy
| | - Fabio Corsi
- Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, via G.B. Grassi 74, 20157 Milan, Italy; Istituti Clinici Scientifici Maugeri IRCCS, via Maugeri 4, 27100 Pavia, Italy.
| | - Marta Truffi
- Istituti Clinici Scientifici Maugeri IRCCS, via Maugeri 4, 27100 Pavia, Italy.
| |
Collapse
|
4
|
Del Nero M, Colombo A, Garbujo S, Baioni C, Barbieri L, Innocenti M, Prosperi D, Colombo M, Fiandra L. Advanced Cell Culture Models Illuminate the Interplay between Mammary Tumor Cells and Activated Fibroblasts. Cancers (Basel) 2023; 15:cancers15092498. [PMID: 37173963 PMCID: PMC10177476 DOI: 10.3390/cancers15092498] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2023] [Revised: 04/21/2023] [Accepted: 04/24/2023] [Indexed: 05/15/2023] Open
Abstract
The interaction between tumor cells and activated fibroblasts determines malignant features of desmoplastic carcinomas such as rapid growth, progression towards a metastatic phenotype, and resistance to chemotherapy. On one hand, tumor cells can activate normal fibroblasts and even reprogram them into CAFs through complex mechanisms that also involve soluble factors. Among them, transforming growth factor beta (TGF-β) and Platelet-Derived Growth Factor (PDGF) have an established role in the acquisition of pro-tumorigenic phenotypes by fibroblasts. On the other hand, activated fibroblasts release Interleukin-6 (IL-6), which increases tumor-cell invasiveness and chemoresistance. However, the interplay between breast cancer cells and fibroblasts, as well as the modes of action of TGF-β, PDGF, and IL-6, are difficult to investigate in vivo. Here, we validated the usage of advanced cell culture models as tools to study the interplay between mammary tumor cells and fibroblasts, taking mouse and human triple-negative tumor cells and fibroblasts as a case study. We employed two different settings, one permitting only paracrine signaling, the other both paracrine and cell-contact-based signaling. These co-culture systems allowed us to unmask how TGF-β, PDGF and IL-6 mediate the interplay between mammary tumor cells and fibroblasts. We found that the fibroblasts underwent activation induced by the TGF-β and the PDGF produced by the tumor cells, which increased their proliferation and IL-6 secretion. The IL-6 secreted by activated fibroblasts enhanced tumor-cell proliferation and chemoresistance. These results show that these breast cancer avatars possess an unexpected high level of complexity, which resembles that observed in vivo. As such, advanced co-cultures provide a pathologically relevant tractable system to study the role of the TME in breast cancer progression with a reductionist approach.
Collapse
Affiliation(s)
- Martina Del Nero
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Alessandro Colombo
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Stefania Garbujo
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Chiara Baioni
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Linda Barbieri
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Metello Innocenti
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Davide Prosperi
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Miriam Colombo
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Luisa Fiandra
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| |
Collapse
|
5
|
Rotem R, Giustra M, Arrigoni F, Bertolini JA, Garbujo S, Rizzuto MA, Salvioni L, Barbieri L, Bertini L, De Gioia L, Colombo M, Prosperi D. Conjugation of gold nanoparticles with multidentate surfactants for enhanced stability and biological properties. J Mater Chem B 2022; 11:61-71. [PMID: 36373865 DOI: 10.1039/d2tb01528e] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
This work originated from the need to functionalize surfactant-coated inorganic nanoparticles for biomedical applications, a process that is limited by excess unbound surfactant. These limitations are connected to the bioconjugation of targeting molecules that are often in equilibrium between the free aliquot in solution and that which binds the surface of the nanoparticles. The excess in solution can play a role in the biocompatability in vitro and in vivo of the final nanoparticles stock. For this purpose, we tested the ability of common surfactants - monothiolated polyethylene glycol and amphiphilic polymers - to colloidally stabilize nanoparticles as excess surfactant is removed and compared them to newly appearing multidentate surfactants endowed with high avidity for inorganic nanoparticles. Our results showed that monothiolated polyethylene glycol or amphiphilic polymers have an insufficient affinity to the nanoparticles and as the excess surfactant is removed the colloidal stability is lost, while multidentate high-avidity surfactants excel in the same regard, possibly allowing improvement in an array of nanoparticle applications, especially in those stated.
Collapse
Affiliation(s)
- Rany Rotem
- Department of Biotechnology and Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126, Milano, Italy.
| | - Marco Giustra
- Department of Biotechnology and Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126, Milano, Italy.
| | - Federica Arrigoni
- Department of Biotechnology and Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126, Milano, Italy.
| | - Jessica A Bertolini
- Department of Biotechnology and Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126, Milano, Italy.
| | - Stefania Garbujo
- Department of Biotechnology and Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126, Milano, Italy.
| | - Maria A Rizzuto
- Department of Biotechnology and Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126, Milano, Italy.
| | - Lucia Salvioni
- Department of Biotechnology and Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126, Milano, Italy.
| | - Linda Barbieri
- Department of Biotechnology and Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126, Milano, Italy.
| | - Luca Bertini
- Department of Biotechnology and Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126, Milano, Italy.
| | - Luca De Gioia
- Department of Biotechnology and Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126, Milano, Italy.
| | - Miriam Colombo
- Department of Biotechnology and Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126, Milano, Italy.
| | - Davide Prosperi
- Department of Biotechnology and Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126, Milano, Italy.
| |
Collapse
|
6
|
Salvioni L, Testa F, Sulejmani A, Pepe F, Giorgio Lovaglio P, Berta P, Dominici R, Leoni V, Prosperi D, Vittadini G, Colombo M, Fiandra L. Surfactant protein D (SP-D) as a biomarker of SARS-CoV-2 infection. Clin Chim Acta 2022; 537:140-145. [PMCID: PMC9617654 DOI: 10.1016/j.cca.2022.10.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2022] [Revised: 10/11/2022] [Accepted: 10/16/2022] [Indexed: 11/05/2022]
Abstract
Background Surfactant protein-D (SP-D) is a lung-resident protein that has emerged as a potential biomarker for COVID-19. Previous investigations on acute respiratory distress syndrome patients demonstrated a significant increment of SP-D serum levels in pathological conditions. Since SP-D is not physiologically permeable to alveoli-capillary membrane and poorly expressed by other tissues, this enhancement is likely due to an impairment of the pulmonary barrier caused by prolonged inflammation. Methods A retrospective study on a relatively large cohort of patients of Hospital Pio XI of Desio was conducted to assess differences of the hematic SP-D concentrations among COVID-19 patients and healthy donors and if SP-D levels resulted a risk factor for disease severity and mortality. Results The first analysis, using an ANOVA-model, showed a significant difference in the mean of log SP-D levels between COVID-19 patients and healthy donors. Significant variations were also found between dead vs survived patients. Results confirm that SP-D concentrations were significantly higher for both hospitalized COVID-19 and dead patients, with threshold values of 150 and 250 ng/mL, respectively. Further analysis conducted with Logistic Mixed models, highlighted that higher SP-D levels at admission and increasing differences among follow-up and admission values resulted the strongest significant risk factors of mortality (model predictive accuracy, AUC = 0.844). Conclusions The results indicate that SP-D can be a predictive marker of COVID-19 disease and its outcome. Considering its prognostic value in terms of mortality, the early detection of SP-D levels and its follow-up in hospitalized patients should be considered to direct the therapeutic intervention.
Collapse
Affiliation(s)
- Lucia Salvioni
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, P.zza della Scienza 2, 20126 Milan, Italy
| | - Filippo Testa
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, P.zza della Scienza 2, 20126 Milan, Italy
| | - Adela Sulejmani
- Department of Medicine and Surgery, University of Milano Bicocca, via Cadore 48, 20900 Monza, Italy
| | - Francesca Pepe
- Department of Medicine and Surgery, University of Milano Bicocca, via Cadore 48, 20900 Monza, Italy
| | - Pietro Giorgio Lovaglio
- Department of Statistics and Quantitative Methods, University of Milano-Bicocca, University of Milano-Bicocca, Via Bicocca degli Arcimboldi 8, 20126 Milan, Italy
| | - Paolo Berta
- Department of Statistics and Quantitative Methods, University of Milano-Bicocca, University of Milano-Bicocca, Via Bicocca degli Arcimboldi 8, 20126 Milan, Italy
| | - Roberto Dominici
- Laboratory of Clinical Biochemistry, Ospedale Pio XI of Desio, ASST-Brianza, via Mazzini 1, 20833 Desio, Italy
| | - Valerio Leoni
- Department of Medicine and Surgery, University of Milano Bicocca, via Cadore 48, 20900 Monza, Italy,Laboratory of Clinical Biochemistry, Ospedale Pio XI of Desio, ASST-Brianza, via Mazzini 1, 20833 Desio, Italy
| | - Davide Prosperi
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, P.zza della Scienza 2, 20126 Milan, Italy
| | - Giorgio Vittadini
- Department of Statistics and Quantitative Methods, University of Milano-Bicocca, University of Milano-Bicocca, Via Bicocca degli Arcimboldi 8, 20126 Milan, Italy
| | - Miriam Colombo
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, P.zza della Scienza 2, 20126 Milan, Italy,Corresponding authors
| | - Luisa Fiandra
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, P.zza della Scienza 2, 20126 Milan, Italy,Corresponding authors
| |
Collapse
|
7
|
Gagliardi S, Truffi M, Tinelli V, Garofalo M, Pandini C, Cotta Ramusino M, Perini G, Costa A, Negri S, Mazzucchelli S, Bonizzi A, Sitia L, Busacca M, Sevieri M, Mocchi M, Ricciardi A, Prosperi D, Corsi F, Cereda C, Morasso C. Bisdemethoxycurcumin (BDC)-Loaded H-Ferritin-Nanocages Mediate the Regulation of Inflammation in Alzheimer's Disease Patients. Int J Mol Sci 2022; 23:9237. [PMID: 36012501 PMCID: PMC9409287 DOI: 10.3390/ijms23169237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2022] [Revised: 08/01/2022] [Accepted: 08/06/2022] [Indexed: 11/24/2022] Open
Abstract
BACKGROUND Bisdemethoxycurcumin (BDC) might be an inflammation inhibitor in Alzheimer's Disease (AD). However, BDC is almost insoluble in water, poorly absorbed by the organism, and degrades rapidly. We thus developed a new nanoformulation of BDC based on H-Ferritin nanocages (BDC-HFn). METHODS We tested the BDC-HFn solubility, stability, and ability to cross a blood-brain barrier (BBB) model. We tested the effect of BDC-HFn on AD and control (CTR) PBMCs to evaluate the transcriptomic profile by RNA-seq. RESULTS We developed a nanoformulation with a diameter of 12 nm to improve the solubility and stability. The comparison of the transcriptomics analyses between AD patients before and after BDC-HFn treatment showed a major number of DEG (2517). The pathway analysis showed that chemokines and macrophages activation differed between AD patients and controls after BDC-HFn treatment. BDC-HFn binds endothelial cells from the cerebral cortex and crosses through a BBB in vitro model. CONCLUSIONS Our data showed how BDC-Hfn could improve the stability of BDC. Significant differences in genes associated with inflammation between the same patients before and after BDC-Hfn treatment have been found. Inflammatory genes that are upregulated between AD and CTR after BDC-HFn treatment are converted and downregulated, suggesting a possible therapeutic approach.
Collapse
Affiliation(s)
| | - Marta Truffi
- Istituti Clinici Scientifici Maugeri IRCCS Spa SB, 27100 Pavia, Italy
| | - Veronica Tinelli
- Department of Biotechnology and Bioscience, University of Milano-Bicocca, 20126 Milano, Italy
| | | | | | | | | | - Alfredo Costa
- IRCCS Mondino Foundation, 27100 Pavia, Italy
- Department of Brain and Behavioral Sciences, University of Pavia, 27100 Pavia, Italy
| | - Sara Negri
- Istituti Clinici Scientifici Maugeri IRCCS Spa SB, 27100 Pavia, Italy
| | - Serena Mazzucchelli
- Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Via G. B. Grassi 74, 20157 Milano, Italy
| | - Arianna Bonizzi
- Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Via G. B. Grassi 74, 20157 Milano, Italy
| | - Leopoldo Sitia
- Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Via G. B. Grassi 74, 20157 Milano, Italy
| | | | - Marta Sevieri
- Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Via G. B. Grassi 74, 20157 Milano, Italy
| | - Michela Mocchi
- Istituti Clinici Scientifici Maugeri IRCCS Spa SB, 27100 Pavia, Italy
| | | | - Davide Prosperi
- Department of Biotechnology and Bioscience, University of Milano-Bicocca, 20126 Milano, Italy
| | - Fabio Corsi
- Istituti Clinici Scientifici Maugeri IRCCS Spa SB, 27100 Pavia, Italy
- Department of Biotechnology and Bioscience, University of Milano-Bicocca, 20126 Milano, Italy
- Department of Brain and Behavioral Sciences, University of Pavia, 27100 Pavia, Italy
- Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Via G. B. Grassi 74, 20157 Milano, Italy
| | | | - Carlo Morasso
- Istituti Clinici Scientifici Maugeri IRCCS Spa SB, 27100 Pavia, Italy
| |
Collapse
|
8
|
Colombo M, Marongiu L, Mingozzi F, Marzi R, Cigni C, Facchini FA, Rotem R, Valache M, Stucchi G, Rocca G, Gornati L, Rizzuto MA, Salvioni L, Zanoni I, Gori A, Prosperi D, Granucci F. Specific immunosuppressive role of nanodrugs targeting calcineurin in innate myeloid cells. iScience 2022; 25:105042. [PMID: 36124235 PMCID: PMC9482116 DOI: 10.1016/j.isci.2022.105042] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2021] [Revised: 05/04/2022] [Accepted: 08/25/2022] [Indexed: 11/27/2022] Open
Abstract
Calcineurin (CN) inhibitors currently used to avoid transplant rejection block the activation of adaptive immune responses but also prevent the development of tolerance toward the graft, by directly inhibiting T cells. CN, through the transcription factors of the NFAT family, plays an important role also in the differentiation dendritic cells (DCs), the main cells responsible for the activation of T lymphocytes. Therefore, we hypothesized that the inhibition of CN only in DCs and not in T cells could be sufficient to prevent T cell responses, while allowing for the development of tolerance. Here, we show that inhibition of CN/NFAT pathway in innate myeloid cells, using a new nanoconjugate capable of selectively targeting phagocytes in vivo, protects against graft rejection and induces a longer graft acceptance compared to common CN inhibitors. We propose a new generation of nanoparticles-based selective immune suppressive agents for a better control of transplant acceptance. Calcineurin/NFATc2 pathway is required to enable DC migration to draining lymph nodes Calcineurin/NFATc2 pathway in DCs is required for type I immune responses activation Superparamagnetic iron oxide NPs can be used to efficiently target phagocytes in vivo Specific delivery of calcineurin inhibitor by NPs to phagocytes induce graft acceptance
Collapse
Affiliation(s)
- Miriam Colombo
- Department of Biotechnology and Biosciences, University of Milano - Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Laura Marongiu
- Department of Biotechnology and Biosciences, University of Milano - Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Francesca Mingozzi
- Department of Biotechnology and Biosciences, University of Milano - Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Roberta Marzi
- Humabs BioMed, Bellinzona, Canton Ticino, Switzerland
| | - Clara Cigni
- Department of Biotechnology and Biosciences, University of Milano - Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Fabio Alessandro Facchini
- Department of Biotechnology and Biosciences, University of Milano - Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Rany Rotem
- Department of Biotechnology and Biosciences, University of Milano - Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Mihai Valache
- Department of Biotechnology and Biosciences, University of Milano - Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Giulia Stucchi
- Department of Biotechnology and Biosciences, University of Milano - Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Giuseppe Rocca
- Department of Biotechnology and Biosciences, University of Milano - Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Laura Gornati
- Department of Biotechnology and Biosciences, University of Milano - Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Maria Antonietta Rizzuto
- Department of Biotechnology and Biosciences, University of Milano - Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Lucia Salvioni
- Department of Biotechnology and Biosciences, University of Milano - Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Ivan Zanoni
- Harvard Medical School and Division of Immunology, Division of Gastroenterology, Boston Children’s Hospital, Boston, MA 02115, USA
| | - Alessandro Gori
- Istituto di Scienze e Tecnologie Chimiche, National Research Council of Italy (SCITEC-CNR), Via Mario Bianco, 9, 20131 Milan, Italy
| | - Davide Prosperi
- Department of Biotechnology and Biosciences, University of Milano - Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
- Corresponding author
| | - Francesca Granucci
- Department of Biotechnology and Biosciences, University of Milano - Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
- Corresponding author
| |
Collapse
|
9
|
Tullio C, Salvioni L, Bellini M, Degrassi A, Fiandra L, D’Arienzo M, Garbujo S, Rotem R, Testa F, Prosperi D, Colombo M. Development of an Effective Tumor-Targeted Contrast Agent for Magnetic Resonance Imaging Based on Mn/H-Ferritin Nanocomplexes. ACS Appl Bio Mater 2021; 4:7800-7810. [PMID: 34805780 PMCID: PMC8596607 DOI: 10.1021/acsabm.1c00724] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2021] [Accepted: 10/08/2021] [Indexed: 11/28/2022]
Abstract
Magnetic resonance imaging (MRI) is one of the most sophisticated diagnostic tools that is routinely used in clinical practice. Contrast agents (CAs) are commonly exploited to afford much clearer images of detectable organs and to reduce the risk of misdiagnosis caused by limited MRI sensitivity. Currently, only a few gadolinium-based CAs are approved for clinical use. Concerns about their toxicity remain, and their administration is approved only under strict controls. Here, we report the synthesis and validation of a manganese-based CA, namely, Mn@HFn-RT. Manganese is an endogenous paramagnetic metal able to produce a positive contrast like gadolinium, but it is thought to result in less toxicity for the human body. Mn ions were efficiently loaded inside the shell of a recombinant H-ferritin (HFn), which is selectively recognized by the majority of human cancer cells through their transferrin receptor 1. Mn@HFn-RT was characterized, showing excellent colloidal stability, superior relaxivity, and a good safety profile. In vitro experiments confirmed the ability of Mn@HFn-RT to efficiently and selectively target breast cancer cells. In vivo, Mn@HFn-RT allowed the direct detection of tumors by positive contrast enhancement in a breast cancer murine model, using very low metal dosages and exhibiting rapid clearance after diagnosis. Hence, Mn@HFn-RT is proposed as a promising CA candidate to be developed for MRI.
Collapse
Affiliation(s)
- Chiara Tullio
- NanoBioLab,
Department of Biotechnology and Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milano, Italy
| | - Lucia Salvioni
- NanoBioLab,
Department of Biotechnology and Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milano, Italy
| | - Michela Bellini
- NanoBioLab,
Department of Biotechnology and Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milano, Italy
| | - Anna Degrassi
- Preclinical
Development, Efficacy and Safety, Accelera
S.R.L.—NMS Group S.p.A., viale Pasteur 10, 20014 Nerviano, MI, Italy
| | - Luisa Fiandra
- NanoBioLab,
Department of Biotechnology and Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milano, Italy
| | - Massimiliano D’Arienzo
- Department
of Materials Science, University of Milano-Bicocca, Via Roberto Cozzi 55, 20125 Milano, Italy
| | - Stefania Garbujo
- NanoBioLab,
Department of Biotechnology and Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milano, Italy
| | - Rany Rotem
- NanoBioLab,
Department of Biotechnology and Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milano, Italy
| | - Filippo Testa
- NanoBioLab,
Department of Biotechnology and Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milano, Italy
| | - Davide Prosperi
- NanoBioLab,
Department of Biotechnology and Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milano, Italy
| | - Miriam Colombo
- NanoBioLab,
Department of Biotechnology and Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milano, Italy
| |
Collapse
|
10
|
Vullo G, De Sanctis V, Anzellini D, Facondo G, Sigillo R, Prosperi D, Riolo D, Osti M. PD-0815 Prognostic role of early FDG-PET/CT in locally advanced cervical carcinoma (LACC) patients. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07094-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
11
|
Arroyo R, Grant SN, Colombo M, Salvioni L, Corsi F, Truffi M, Ottolina D, Hurst B, Salzberg M, Prosperi D, Kingma PS. Full-Length Recombinant hSP-D Binds and Inhibits SARS-CoV-2. Biomolecules 2021; 11:1114. [PMID: 34439781 PMCID: PMC8393632 DOI: 10.3390/biom11081114] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2021] [Revised: 07/21/2021] [Accepted: 07/23/2021] [Indexed: 12/15/2022] Open
Abstract
SARS-CoV-2 infection of host cells is driven by binding of the SARS-CoV-2 spike-(S)-protein to lung type II pneumocytes, followed by virus replication. Surfactant protein SP-D, member of the front-line immune defense of the lungs, binds glycosylated structures on invading pathogens such as viruses to induce their clearance from the lungs. The objective of this study is to measure the pulmonary SP-D levels in COVID-19 patients and demonstrate the activity of SP-D against SARS-CoV-2, opening the possibility of using SP-D as potential therapy for COVID-19 patients. Pulmonary SP-D concentrations were measured in bronchoalveolar lavage samples from patients with corona virus disease 2019 (COVID-19) by anti-SP-D ELISA. Binding assays were performed by ELISAs. Protein bridge and aggregation assays were performed by gel electrophoresis followed by silver staining and band densitometry. Viral replication was evaluated in vitro using epithelial Caco-2 cells. Results indicate that COVID-19 patients (n = 12) show decreased pulmonary levels of SP-D (median = 68.9 ng/mL) when compared to levels reported for healthy controls in literature. Binding assays demonstrate that SP-D binds the SARS-CoV-2 glycosylated spike-(S)-protein of different emerging clinical variants. Binding induces the formation of protein bridges, the critical step of viral aggregation to facilitate its clearance. SP-D inhibits SARS-CoV-2 replication in Caco-2 cells (EC90 = 3.7 μg/mL). Therefore, SP-D recognizes and binds to the spike-(S)-protein of SARS-CoV-2 in vitro, initiates the aggregation, and inhibits viral replication in cells. Combined with the low levels of SP-D observed in COVID-19 patients, these results suggest that SP-D is important in the immune response to SARS-CoV-2 and that rhSP-D supplementation has the potential to be a novel class of anti-viral that will target SARS-CoV-2 infection.
Collapse
Affiliation(s)
- Raquel Arroyo
- Division of Neonatology and Pulmonary Biology, Cincinnati Children’s Hospital, Cincinnati, OH 45229, USA;
| | - Shawn N. Grant
- Airway Therapeutics Inc., Cincinnati, OH 45249, USA; (S.N.G.); (M.S.)
| | - Miriam Colombo
- NanoBio laboratory, Department of Biotechnology and Bioscience, University of Milano-Bicocca, 20126 Milano, Italy; (M.C.); (L.S.); (D.P.)
| | - Lucia Salvioni
- NanoBio laboratory, Department of Biotechnology and Bioscience, University of Milano-Bicocca, 20126 Milano, Italy; (M.C.); (L.S.); (D.P.)
| | - Fabio Corsi
- Istituti Clinici Scientifici Maugeri IRCCS, via Maugeri 4, 27100 Pavia, Italy; (F.C.); (M.T.)
| | - Marta Truffi
- Istituti Clinici Scientifici Maugeri IRCCS, via Maugeri 4, 27100 Pavia, Italy; (F.C.); (M.T.)
| | - Davide Ottolina
- Division of Anesthesiology and Intensive Care Medicine, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, University of Milan, 20157 Milano, Italy;
| | - Brett Hurst
- Institute for Antiviral Research, Utah State University, Logan, UT 84322, USA;
| | - Marc Salzberg
- Airway Therapeutics Inc., Cincinnati, OH 45249, USA; (S.N.G.); (M.S.)
| | - Davide Prosperi
- NanoBio laboratory, Department of Biotechnology and Bioscience, University of Milano-Bicocca, 20126 Milano, Italy; (M.C.); (L.S.); (D.P.)
| | - Paul S. Kingma
- Division of Neonatology and Pulmonary Biology, Cincinnati Children’s Hospital, Cincinnati, OH 45229, USA;
- Department of Pediatrics, University of Cincinnati, Cincinnati, OH 45229, USA
| |
Collapse
|
12
|
Salvioni L, Morelli L, Ochoa E, Labra M, Fiandra L, Palugan L, Prosperi D, Colombo M. The emerging role of nanotechnology in skincare. Adv Colloid Interface Sci 2021; 293:102437. [PMID: 34023566 DOI: 10.1016/j.cis.2021.102437] [Citation(s) in RCA: 56] [Impact Index Per Article: 18.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2021] [Revised: 05/06/2021] [Accepted: 05/07/2021] [Indexed: 02/07/2023]
Abstract
The role of cosmetic products is rapidly evolving in our society, with their use increasingly seen as an essential contribution to personal wellness. This suggests the necessity of a detailed elucidation of the use of nanoparticles (NPs) in cosmetics. The aim of the present work is to offer a critical and comprehensive review discussing the impact of exploiting nanomaterials in advanced cosmetic formulations, emphasizing the beneficial effects of their extensive use in next-generation products despite a persisting prejudice around the application of nanotechnology in cosmetics. The discussion here includes an interpretation of the data underlying generic information reported on the product labels of formulations already available in the marketplace, information that often lacks details identifying specific components of the product, especially when nanomaterials are employed. The emphasis of this review is mainly focused on skincare because it is believed to be the cosmetics market sector in which the impact of nanotechnology is being seen most significantly. To date, nanotechnology has been demonstrated to improve the performance of cosmetics in a number of different ways: 1) increasing both the entrapment efficiency and dermal penetration of the active ingredient, 2) controlling drug release, 3) enhancing physical stability, 4) improving moisturizing power, and 5) providing better UV protection. Specific attention is paid to the effect of nanoparticles contained in semisolid formulations on skin penetration issues. In light of the emerging concerns about nanoparticle toxicity, an entire section has been devoted to listing detailed examples of nanocosmetic products for which safety has been investigated.
Collapse
|
13
|
Garbujo S, Galbiati E, Salvioni L, Mazzucchelli M, Frascotti G, Sun X, Megahed S, Feliu N, Prosperi D, Parak WJ, Colombo M. Functionalization of colloidal nanoparticles with a discrete number of ligands based on a "HALO-bioclick" reaction. Chem Commun (Camb) 2021; 56:11398-11401. [PMID: 32990290 DOI: 10.1039/d0cc04355a] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
A recombinant HALO-GFP fusion protein was designed and isolated to demonstrate the feasibility of controlling the number and orientation of protein ligands to be conjugated on colloidal gold nanoparticles. AuNPs functionalized with exactly one or exactly two GFP molecules exhibited fully preserved functionality of the protein. The method is very straightforward and generally provides highly bioactive nanoparticle-protein conjugates.
Collapse
Affiliation(s)
- Stefania Garbujo
- NanoBioLab, Department of Biotechnology and Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milano, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Rinzivillo M, Prosperi D, Mazzuca F, Magi L, Iannicelli E, Pilozzi E, Franchi G, Laghi A, Annibale B, Signore A, Panzuto F. [ 18F]FDG-PET/CT and long-term responses to everolimus in advanced neuroendocrine neoplasia. J Endocrinol Invest 2021; 44:811-818. [PMID: 32767279 DOI: 10.1007/s40618-020-01378-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/28/2020] [Accepted: 07/30/2020] [Indexed: 02/08/2023]
Abstract
PURPOSE This study aims to identify in patients with neuroendocrine neoplasia (NEN) the potential correlation between FDG-PET findings and responses to everolimus therapy to identify predictors of long-term efficacy. METHODS Retrospective analysis of patients with sporadic, advanced, progressive NEN treated with everolimus was performed based on the available data on FDG-PET patients obtained before commencing therapy. Data are expressed as the median (25-75th IQR). Risk factor analysis and survival analysis were performed by logistic regression and Cox proportional hazard regression and the determination of Kaplan-Meier curves, as appropriate. RESULTS Sixty-six patients were evaluated (NET G1 19.7%, NET G2 75.7%, and NET G3 4.6%), including 45.4% with positive FDG-PET findings. Overall, disease stabilization and a partial response were achieved for 71.2% and 6% of patients, respectively. A long-term response (> 24 months) was observed in 33% of patients. Ki67 was the only predictor of tumor progression (p = 0.03). No significant difference in clinical outcomes was observed between patients with positive or negative FDG-PET findings (median PFS was 24 months and 18 months, respectively, p = 0.337; the disease control rate was 83.3% and 70%, respectively, p = 0.245). CONCLUSIONS Everolimus is a valid therapeutic option for advanced, progressive, well-differentiated NEN, even in patients with positive FDG-PET findings.
Collapse
Affiliation(s)
- M Rinzivillo
- Digestive Disease Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, Via di Grottarossa 1035, 00189, Rome, Italy
| | - D Prosperi
- Nuclear Medicine Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, Rome, Italy
| | - F Mazzuca
- Medical Oncology Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, Rome, Italy
- Department of Clinical and Molecular Medicine, "Sapienza" University of Rome, Rome, Italy
| | - L Magi
- Digestive Disease Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, Via di Grottarossa 1035, 00189, Rome, Italy
| | - E Iannicelli
- Radiology Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, Rome, Italy
- Department of Medical-Surgical Sciences and of Translational Medicine, "Sapienza" University of Rome, Rome, Italy
| | - E Pilozzi
- Department of Clinical and Molecular Medicine, "Sapienza" University of Rome, Rome, Italy
- Pathology Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, Rome, Italy
| | - G Franchi
- Nuclear Medicine Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, Rome, Italy
| | - A Laghi
- Radiology Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, Rome, Italy
- Department of Medical-Surgical Sciences and of Translational Medicine, "Sapienza" University of Rome, Rome, Italy
| | - B Annibale
- Digestive Disease Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, Via di Grottarossa 1035, 00189, Rome, Italy
- Department of Medical-Surgical Sciences and of Translational Medicine, "Sapienza" University of Rome, Rome, Italy
| | - A Signore
- Nuclear Medicine Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, Rome, Italy
- Department of Medical-Surgical Sciences and of Translational Medicine, "Sapienza" University of Rome, Rome, Italy
| | - F Panzuto
- Digestive Disease Unit, ENETS Center of Excellence, Sant'Andrea University Hospital, Via di Grottarossa 1035, 00189, Rome, Italy.
| |
Collapse
|
15
|
Marongiu L, Mingozzi F, Cigni C, Marzi R, Di Gioia M, Garrè M, Parazzoli D, Sironi L, Collini M, Sakaguchi R, Morii T, Crosti M, Moro M, Schurmans S, Catelani T, Rotem R, Colombo M, Shears S, Prosperi D, Zanoni I, Granucci F. Inositol 1,4,5-trisphosphate 3-kinase B promotes Ca 2+ mobilization and the inflammatory activity of dendritic cells. Sci Signal 2021; 14:14/676/eaaz2120. [PMID: 33785611 DOI: 10.1126/scisignal.aaz2120] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Innate immune responses to Gram-negative bacteria depend on the recognition of lipopolysaccharide (LPS) by a receptor complex that includes CD14 and TLR4. In dendritic cells (DCs), CD14 enhances the activation not only of TLR4 but also that of the NFAT family of transcription factors, which suppresses cell survival and promotes the production of inflammatory mediators. NFAT activation requires Ca2+ mobilization. In DCs, Ca2+ mobilization in response to LPS depends on phospholipase C γ2 (PLCγ2), which produces inositol 1,4,5-trisphosphate (IP3). Here, we showed that the IP3 receptor 3 (IP3R3) and ITPKB, a kinase that converts IP3 to inositol 1,3,4,5-tetrakisphosphate (IP4), were both necessary for Ca2+ mobilization and NFAT activation in mouse and human DCs. A pool of IP3R3 was located on the plasma membrane of DCs, where it colocalized with CD14 and ITPKB. Upon LPS binding to CD14, ITPKB was required for Ca2+ mobilization through plasma membrane-localized IP3R3 and for NFAT nuclear translocation. Pharmacological inhibition of ITPKB in mice reduced both LPS-induced tissue swelling and the severity of inflammatory arthritis to a similar extent as that induced by the inhibition of NFAT using nanoparticles that delivered an NFAT-inhibiting peptide specifically to phagocytic cells. Our results suggest that ITPKB may represent a promising target for anti-inflammatory therapies that aim to inhibit specific DC functions.
Collapse
Affiliation(s)
- Laura Marongiu
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Francesca Mingozzi
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Clara Cigni
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Roberta Marzi
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Marco Di Gioia
- Harvard Medical School and Division of Immunology, Division of Gastroenterology, Boston Children's Hospital, Boston, MA 02115, USA
| | | | | | - Laura Sironi
- Department of Physics, University of Milano-Bicocca, Piazza della Scienza 3, 20126 Milan, Italy
| | - Maddalena Collini
- Department of Physics, University of Milano-Bicocca, Piazza della Scienza 3, 20126 Milan, Italy
| | - Reiko Sakaguchi
- Institute for Integrated Cell-Material Sciences, Kyoto University Katsura, Nishikyo-ku, Kyoto 615-8510, Japan
| | - Takashi Morii
- Institute of Advanced Energy, Kyoto University, Uji, Kyoto 611-0011, Japan
| | - Mariacristina Crosti
- INGM, Istituto Nazionale di Genetica Molecolare "Romeo ed Enrica Invernizzi", 20122 Milan, Italy
| | - Monica Moro
- INGM, Istituto Nazionale di Genetica Molecolare "Romeo ed Enrica Invernizzi", 20122 Milan, Italy
| | - Stéphane Schurmans
- Laboratory of Functional Genetics, GIGA-B34, University of Liège, 4000 Liège, Belgium
| | - Tiziano Catelani
- Piattaforma Interdipartimentale di Microscopia, University of Milano-Bicocca, Piazza della Scienza 3, 20126 Milan, Italy
| | - Rany Rotem
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Miriam Colombo
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Stephen Shears
- Signal Transduction Laboratory, NIEHS/NIH, 111 TW Alexander Drive, Research Triangle Park, NC 27709, USA
| | - Davide Prosperi
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Ivan Zanoni
- Harvard Medical School and Division of Immunology, Division of Gastroenterology, Boston Children's Hospital, Boston, MA 02115, USA.,Division of Immunology, Harvard Medical School, Boston Children's Hospital, Boston, MA 02115, USA
| | - Francesca Granucci
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy. .,INGM, Istituto Nazionale di Genetica Molecolare "Romeo ed Enrica Invernizzi", 20122 Milan, Italy
| |
Collapse
|
16
|
Rizzuto MA, Dal Magro R, Barbieri L, Pandolfi L, Sguazzini-Viscontini A, Truffi M, Salvioni L, Corsi F, Colombo M, Re F, Prosperi D. H-Ferritin nanoparticle-mediated delivery of antibodies across a BBB in vitro model for treatment of brain malignancies. Biomater Sci 2021; 9:2032-2042. [PMID: 33544109 DOI: 10.1039/d0bm01726d] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Brain cancers are a group of neoplasms that can be either primary, such as glioblastoma multiforme (GBM), or metastatic, such as the HER2+ breast cancer brain metastasis. The brain represents a sanctuary for cancer cells thanks to the presence of the blood brain barrier (BBB) that controls trafficking of molecules, protecting the brain from toxic substances including drugs. Considering that GBM and HER2+ breast cancer brain metastases are characterized by EGFR and HER2 over-expression respectively, CTX- and TZ-based treatment could be effective. Several studies show that these monoclonal antibodies (mAbs) exert both a cytostatic activity interfering with the transduction pathways of EGFR family and a cytotoxic activity mainly through the immune system activation via the antibody dependent cell-mediated cytotoxicity (ADCC). Since the major limitation to therapeutic mAbs application is the presence of the BBB, here we use a recombinant form of human apoferritin (HFn) as a nanovector to promote the delivery of mAbs to the brain for the activation of the ADCC response. Using a transwell model of the BBB we proved the crossing ability of HFn-mAb. Cellular uptake of HFn-mAb by human cerebral microvascular endothelial cells (hCMEC/D3) was demonstrated by confocal microscopy. Moreover, after crossing the endothelial monolayer, HFn-conjugated mAbs retain their biological activity against targets, as assessed by MTS and ADCC assays. Our data support the use of HFn as efficient carrier to enhance the BBB crossing of mAbs, without affecting their antitumoral activity.
Collapse
Affiliation(s)
- Maria Antonietta Rizzuto
- NanoBioLab, Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Rensi N, Sammarco A, Moccia V, Calore A, Torrigiani F, Prosperi D, Rizzuto MA, Bellini M, De Maria R, Bonsembiante F, Ferro S, Zanetti R, Zappulli V, Cavicchioli L. Evaluation of TFR-1 Expression in Feline Mammary Cancer and In Vitro Antitumor Efficacy Study of Doxorubicin-Loaded H-Ferritin Nanocages. Cancers (Basel) 2021; 13:cancers13061248. [PMID: 33809013 PMCID: PMC8000254 DOI: 10.3390/cancers13061248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2021] [Revised: 03/08/2021] [Accepted: 03/09/2021] [Indexed: 12/05/2022] Open
Abstract
Simple Summary Transferrin receptor one (TFR-1), recognized by ferritin, is overexpressed in many tumor cells. This feature has been exploited to produce a selective overload of drugs within tumor cells by creating an engineered ferritin nanocage loaded with doxorubicin (HFn(DOX)). This bionanotechnology has been tested in human cancer, but there are no studies in veterinary oncology. This work, after evaluating the expression of TFR-1 in feline tumors, demonstrated for the first time the effectiveness in vitro of this nanocage in animals. These results confirm that engineered bionanocages also offer unprecedented opportunities for animal cancer to be applied in veterinary medicine and in comparative studies including spontaneous animal models of cancer. Abstract The transferrin receptor 1 (TFR-1) has been found overexpressed in a broad range of solid tumors in humans and is, therefore, attracting great interest in clinical oncology for innovative targeted therapies, including nanomedicine. TFR-1 is recognized by H-Ferritin (HFn) and has been exploited to allow selective binding and drug internalization, applying an HFn nanocage loaded with doxorubicin (HFn(DOX)). In veterinary medicine, the role of TFR-1 in animal cancers remains poorly explored, and no attempts to use TFR-1 as a target for drug delivery have been conducted so far. In this study, we determined the TFR-1 expression both in feline mammary carcinomas during tumor progression, as compared to healthy tissue, and, in vitro, in a feline metastatic mammary cancer cell line. The efficacy of HFn(DOX) was compared to treatment with conventional doxorubicin in feline mammary cancer cells. Our results highlighted an increased TFR-1 expression associated with tumor metastatic progression, indicating a more aggressive behavior. Furthermore, it was demonstrated that the use of HFn(DOX) resulted in less proliferation of cells and increased apoptosis when compared to the drug alone. The results of this preliminary study suggest that the use of engineered bionanocages also offers unprecedented opportunities for selective targeted chemotherapy of solid tumors in veterinary medicine.
Collapse
Affiliation(s)
- Nicolò Rensi
- Department of Comparative Biomedicine and Food Science, University of Padua, 35020 Padua, Italy; (A.S.); (V.M.); (A.C.); (F.T.); (F.B.); (S.F.); (R.Z.); (V.Z.); (L.C.)
- Correspondence:
| | - Alessandro Sammarco
- Department of Comparative Biomedicine and Food Science, University of Padua, 35020 Padua, Italy; (A.S.); (V.M.); (A.C.); (F.T.); (F.B.); (S.F.); (R.Z.); (V.Z.); (L.C.)
- Department of Neurology and Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
| | - Valentina Moccia
- Department of Comparative Biomedicine and Food Science, University of Padua, 35020 Padua, Italy; (A.S.); (V.M.); (A.C.); (F.T.); (F.B.); (S.F.); (R.Z.); (V.Z.); (L.C.)
| | - Alessandro Calore
- Department of Comparative Biomedicine and Food Science, University of Padua, 35020 Padua, Italy; (A.S.); (V.M.); (A.C.); (F.T.); (F.B.); (S.F.); (R.Z.); (V.Z.); (L.C.)
| | - Filippo Torrigiani
- Department of Comparative Biomedicine and Food Science, University of Padua, 35020 Padua, Italy; (A.S.); (V.M.); (A.C.); (F.T.); (F.B.); (S.F.); (R.Z.); (V.Z.); (L.C.)
| | - Davide Prosperi
- NanoBiolab, Department of Biotechnology and Bioscience, University of Milano-Bicocca, 20126 Milan, Italy; (D.P.); (M.A.R.); (M.B.)
| | - Maria Antonietta Rizzuto
- NanoBiolab, Department of Biotechnology and Bioscience, University of Milano-Bicocca, 20126 Milan, Italy; (D.P.); (M.A.R.); (M.B.)
| | - Michela Bellini
- NanoBiolab, Department of Biotechnology and Bioscience, University of Milano-Bicocca, 20126 Milan, Italy; (D.P.); (M.A.R.); (M.B.)
| | - Raffaella De Maria
- Department of Veterinary Science, University of Turin, 10095 Turin, Italy;
| | - Federico Bonsembiante
- Department of Comparative Biomedicine and Food Science, University of Padua, 35020 Padua, Italy; (A.S.); (V.M.); (A.C.); (F.T.); (F.B.); (S.F.); (R.Z.); (V.Z.); (L.C.)
- Department of Animal Medicine, Productions and Health, University of Padua, 35020 Padua, Italy
| | - Silvia Ferro
- Department of Comparative Biomedicine and Food Science, University of Padua, 35020 Padua, Italy; (A.S.); (V.M.); (A.C.); (F.T.); (F.B.); (S.F.); (R.Z.); (V.Z.); (L.C.)
| | - Rossella Zanetti
- Department of Comparative Biomedicine and Food Science, University of Padua, 35020 Padua, Italy; (A.S.); (V.M.); (A.C.); (F.T.); (F.B.); (S.F.); (R.Z.); (V.Z.); (L.C.)
| | - Valentina Zappulli
- Department of Comparative Biomedicine and Food Science, University of Padua, 35020 Padua, Italy; (A.S.); (V.M.); (A.C.); (F.T.); (F.B.); (S.F.); (R.Z.); (V.Z.); (L.C.)
| | - Laura Cavicchioli
- Department of Comparative Biomedicine and Food Science, University of Padua, 35020 Padua, Italy; (A.S.); (V.M.); (A.C.); (F.T.); (F.B.); (S.F.); (R.Z.); (V.Z.); (L.C.)
| |
Collapse
|
18
|
Rainone P, De Palma A, Sudati F, Roffia V, Rigamonti V, Salvioni L, Colombo M, Ripamonti M, Spinelli AE, Mazza D, Mauri P, Moresco RM, Prosperi D, Belloli S. 99mTc-Radiolabeled Silica Nanocarriers for Targeted Detection and Treatment of HER2-Positive Breast Cancer. Int J Nanomedicine 2021; 16:1943-1960. [PMID: 33727808 PMCID: PMC7954038 DOI: 10.2147/ijn.s276033] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2020] [Accepted: 10/24/2020] [Indexed: 12/22/2022] Open
Abstract
INTRODUCTION The overexpression of Human Epidermal Growth Factor Receptor 2 (HER2) is usually associated with aggressive and infiltrating breast cancer (BC) phenotype, and metastases. Functionalized silica-based nanocarriers (SiNPs) can be labeled for in vivo imaging applications and loaded with chemotherapy drugs, making possible the simultaneous noninvasive diagnosis and treatment (theranostic) for HER2-positive BC. METHODS Firstly, FITC-filled SiNPs, were engineered with two different amounts of Hc-TZ (trastuzumab half-chain) per single nanoparticle (1:2 and 1:8, SiNPs to Hc-TZ ratio), which was 99mTc-radiolabeled at histidine residues for ex vivo and in vivo biodistribution evaluations. Secondly, nanoparticles were loaded with DOX and their in vitro and ex vivo/in vivo delivery was assessed, in comparison with liposomal Doxorubicin (Caelyx). Finally, the treatment efficacy of DOX-SiNPs-TZ (1:8 Hc-TZ) was evaluated in vivo by PET and supported by MS-based proteomics profiling of tumors. RESULTS SiNPs-TZ (1:8 Hc-TZ) tumor uptake was significantly greater than that of SiNPs-TZ (1:2 Hc-TZ) at 6 hours post-injection (p.i.) in ex vivo biodistribution experiment. At 24 h p.i., radioactivity values remained steady. Fluorescence microscopy, confirmed the presence of radiolabeled SiNPs-TZ (1:8 Hc-TZ) within tumor even at later times. SiNPs-TZ (1:8 Hc-TZ) nanoparticles loaded with Doxorubicin (DOX-SiNPs-TZ) showed a similar DOX delivery capability than Caelyx (at 6 h p.i.), in in vitro and ex vivo assays. Nevertheless, at the end of treatment, tumor volume was significantly reduced by DOX-SiNPs-TZ (1:8 Hc-TZ), compared to Caelyx and DOX-SiNPs treatment. Proteomics study identified 88 high stringent differentially expressed proteins comparing the three treatment groups with controls. CONCLUSION These findings demonstrated a promising detection specificity and treatment efficacy for our system (SiNPs-TZ, 1:8 Hc-TZ), encouraging its potential use as a new theranostic agent for HER2-positive BC lesions. In addition, proteomic profile confirmed that a set of proteins, related to tumor aggressiveness, were positively affected by targeted nanoparticles.
Collapse
Affiliation(s)
- Paolo Rainone
- Department of Medicine and Surgery, University of Milano-Bicocca, Monza, 20900, Italy
- Institute of Molecular Bioimaging and Physiology of CNR, Segrate, 20090, Italy
- Doctorate School of Molecular and Translational Medicine, University of Milan, Milan, Italy
| | | | - Francesco Sudati
- PET and Nuclear Medicine Unit, San Raffaele Scientific Institute, Milan, 20132, Italy
| | - Valentina Roffia
- Institute of Biomedical Technologies of CNR, Segrate, 20090, Italy
| | - Valentina Rigamonti
- NanoBioLab, Department of Biotechnology and Biosciences, University of Milano-Bicocca, Milan, 20126, Italy
| | - Lucia Salvioni
- NanoBioLab, Department of Biotechnology and Biosciences, University of Milano-Bicocca, Milan, 20126, Italy
| | - Miriam Colombo
- NanoBioLab, Department of Biotechnology and Biosciences, University of Milano-Bicocca, Milan, 20126, Italy
| | - Marilena Ripamonti
- Institute of Molecular Bioimaging and Physiology of CNR, Segrate, 20090, Italy
| | | | - Davide Mazza
- Experimental Imaging Center, San Raffaele Scientific Institute, Milan, 20132, Italy
| | - Pierluigi Mauri
- Institute of Biomedical Technologies of CNR, Segrate, 20090, Italy
| | - Rosa Maria Moresco
- Department of Medicine and Surgery, University of Milano-Bicocca, Monza, 20900, Italy
- Institute of Molecular Bioimaging and Physiology of CNR, Segrate, 20090, Italy
- Experimental Imaging Center, San Raffaele Scientific Institute, Milan, 20132, Italy
| | - Davide Prosperi
- NanoBioLab, Department of Biotechnology and Biosciences, University of Milano-Bicocca, Milan, 20126, Italy
| | - Sara Belloli
- Institute of Molecular Bioimaging and Physiology of CNR, Segrate, 20090, Italy
- Experimental Imaging Center, San Raffaele Scientific Institute, Milan, 20132, Italy
| |
Collapse
|
19
|
Sitia L, Bonizzi A, Mazzucchelli S, Negri S, Sottani C, Grignani E, Rizzuto MA, Prosperi D, Sorrentino L, Morasso C, Allevi R, Sevieri M, Silva F, Truffi M, Corsi F. Selective Targeting of Cancer-Associated Fibroblasts by Engineered H-Ferritin Nanocages Loaded with Navitoclax. Cells 2021; 10:328. [PMID: 33562504 PMCID: PMC7915356 DOI: 10.3390/cells10020328] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2020] [Revised: 01/29/2021] [Accepted: 02/02/2021] [Indexed: 12/13/2022] Open
Abstract
Cancer-associated fibroblasts (CAFs) are key actors in regulating cancer progression. They promote tumor growth, metastasis formation, and induce drug resistance. For these reasons, they are emerging as potential therapeutic targets. Here, with the aim of developing CAF-targeted drug delivery agents, we functionalized H-ferritin (HFn) nanocages with fibroblast activation protein (FAP) antibody fragments. Functionalized nanocages (HFn-FAP) have significantly higher binding with FAP+ CAFs than with FAP- cancer cells. We loaded HFn-FAP with navitoclax (Nav), an experimental Bcl-2 inhibitor pro-apoptotic drug, whose clinical development is limited by its strong hydrophobicity and toxicity. We showed that Nav is efficiently loaded into HFn (HNav), maintaining its mechanism of action. Incubating Nav-loaded functionalized nanocages (HNav-FAP) with FAP+ cells, we found significantly higher cytotoxicity as compared to non-functionalized HNav. This was correlated with a significantly higher drug release only in FAP+ cells, confirming the specific targeting ability of functionalized HFn. Finally, we showed that HFn-FAP is able to reach the tumor and to target CAFs in a mouse syngeneic model of triple negative breast cancer after intravenous administration. Our data show that HNav-FAP could be a promising tool to enhance specific drug delivery into CAFs, thus opening new therapeutic possibilities focused on tumor microenvironment.
Collapse
Affiliation(s)
- Leopoldo Sitia
- Dipartimento di Scienze Biomediche e Cliniche “L. Sacco”, Università di Milano, 20157 Milan, Italy; (L.S.); (A.B.); (S.M.); (R.A.); (M.S.); (F.S.)
| | - Arianna Bonizzi
- Dipartimento di Scienze Biomediche e Cliniche “L. Sacco”, Università di Milano, 20157 Milan, Italy; (L.S.); (A.B.); (S.M.); (R.A.); (M.S.); (F.S.)
| | - Serena Mazzucchelli
- Dipartimento di Scienze Biomediche e Cliniche “L. Sacco”, Università di Milano, 20157 Milan, Italy; (L.S.); (A.B.); (S.M.); (R.A.); (M.S.); (F.S.)
| | - Sara Negri
- Istituti Clinici Scientifici Maugeri IRCCS, 27100 Pavia, Italy; (S.N.); (C.S.); (E.G.); (C.M.)
| | - Cristina Sottani
- Istituti Clinici Scientifici Maugeri IRCCS, 27100 Pavia, Italy; (S.N.); (C.S.); (E.G.); (C.M.)
| | - Elena Grignani
- Istituti Clinici Scientifici Maugeri IRCCS, 27100 Pavia, Italy; (S.N.); (C.S.); (E.G.); (C.M.)
| | - Maria Antonietta Rizzuto
- Department of Biotechnology and Biosciences, University of Milan-Bicocca, 20126 Milan, Italy; (M.A.R.); (D.P.)
| | - Davide Prosperi
- Department of Biotechnology and Biosciences, University of Milan-Bicocca, 20126 Milan, Italy; (M.A.R.); (D.P.)
| | - Luca Sorrentino
- Colorectal Surgery Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milan, Italy;
| | - Carlo Morasso
- Istituti Clinici Scientifici Maugeri IRCCS, 27100 Pavia, Italy; (S.N.); (C.S.); (E.G.); (C.M.)
| | - Raffaele Allevi
- Dipartimento di Scienze Biomediche e Cliniche “L. Sacco”, Università di Milano, 20157 Milan, Italy; (L.S.); (A.B.); (S.M.); (R.A.); (M.S.); (F.S.)
| | - Marta Sevieri
- Dipartimento di Scienze Biomediche e Cliniche “L. Sacco”, Università di Milano, 20157 Milan, Italy; (L.S.); (A.B.); (S.M.); (R.A.); (M.S.); (F.S.)
| | - Filippo Silva
- Dipartimento di Scienze Biomediche e Cliniche “L. Sacco”, Università di Milano, 20157 Milan, Italy; (L.S.); (A.B.); (S.M.); (R.A.); (M.S.); (F.S.)
| | - Marta Truffi
- Istituti Clinici Scientifici Maugeri IRCCS, 27100 Pavia, Italy; (S.N.); (C.S.); (E.G.); (C.M.)
| | - Fabio Corsi
- Dipartimento di Scienze Biomediche e Cliniche “L. Sacco”, Università di Milano, 20157 Milan, Italy; (L.S.); (A.B.); (S.M.); (R.A.); (M.S.); (F.S.)
- Istituti Clinici Scientifici Maugeri IRCCS, 27100 Pavia, Italy; (S.N.); (C.S.); (E.G.); (C.M.)
| |
Collapse
|
20
|
Pandolfi L, Fusco R, Frangipane V, D'Amico R, Giustra M, Bozzini S, Morosini M, D'Amato M, Cova E, Ferrario G, Morbini P, Colombo M, Prosperi D, Viglio S, Piloni D, Di Paola R, Cuzzocrea S, Meloni F. Loading Imatinib inside targeted nanoparticles to prevent Bronchiolitis Obliterans Syndrome. Sci Rep 2020; 10:20726. [PMID: 33244143 PMCID: PMC7693282 DOI: 10.1038/s41598-020-77828-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Accepted: 11/12/2020] [Indexed: 12/24/2022] Open
Abstract
Bronchiolitis Obliterans Syndrome seriously reduces long-term survival of lung transplanted patients. Up to now there is no effective therapy once BOS is established. Nanomedicine introduces the possibility to administer drugs locally into lungs increasing drug accumulation in alveola reducing side effects. Imatinib was loaded in gold nanoparticles (GNP) functionalized with antibody against CD44 (GNP-HCIm). Lung fibroblasts (LFs) were derived from bronchoalveolar lavage of BOS patients. GNP-HCIm cytotoxicity was evaluated by MTT assay, apoptosis/necrosis and phosphorylated-cAbl (cAbl-p). Heterotopic tracheal transplantation (HTT) mouse model was used to evaluate the effect of local GNP-HCIm administration by Alzet pump. GNP-HCIm decreased LFs viability compared to Imatinib (44.4 ± 1.8% vs. 91.8 ± 3.2%, p < 0.001), inducing higher apoptosis (22.68 ± 4.3% vs. 6.43 ± 0.29; p < 0.001) and necrosis (18.65 ± 5.19%; p < 0.01). GNP-HCIm reduced cAbl-p (0.41 GNP-HCIm, 0.24 Imatinib vs. to control; p < 0.001). GNP-HCIm in HTT mouse model by Alzet pump significantly reduced tracheal lumen obliteration (p < 0.05), decreasing apoptosis (p < 0.05) and TGF-β-positive signal (p < 0.05) in surrounding tissue. GNP-HCIm treatment significantly reduced lymphocytic and neutrophil infiltration and mast cells degranulation (p < 0.05). Encapsulation of Imatinib into targeted nanoparticles could be considered a new option to inhibit the onset of allograft rejection acting on BOS specific features.
Collapse
Affiliation(s)
- Laura Pandolfi
- Research Laboratory of Lung Diseases, Section of Cell Biology, IRCCS Policlinico San Matteo Foundation, 27100, Pavia, Italy.
| | - Roberta Fusco
- Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of Messina, 981000, Messina, Italy
| | - Vanessa Frangipane
- Research Laboratory of Lung Diseases, Section of Cell Biology, IRCCS Policlinico San Matteo Foundation, 27100, Pavia, Italy
| | - Ramona D'Amico
- Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of Messina, 981000, Messina, Italy
| | - Marco Giustra
- NanoBioLab, Department of Biotechnology and Biosciences, University of Milano-Bicocca, 20100, Milano, Italy
| | - Sara Bozzini
- Research Laboratory of Lung Diseases, Section of Cell Biology, IRCCS Policlinico San Matteo Foundation, 27100, Pavia, Italy
| | - Monica Morosini
- Research Laboratory of Lung Diseases, Section of Cell Biology, IRCCS Policlinico San Matteo Foundation, 27100, Pavia, Italy
| | - Maura D'Amato
- Research Laboratory of Lung Diseases, Section of Cell Biology, IRCCS Policlinico San Matteo Foundation, 27100, Pavia, Italy
| | - Emanuela Cova
- Department of Molecular Medicine, Pathology Unit, University of Pavia; IRCCS Foundation Policlinico San Matteo, 27100, Pavia, Italy
| | - Giuseppina Ferrario
- Department of Molecular Medicine, Pathology Unit, University of Pavia; IRCCS Foundation Policlinico San Matteo, 27100, Pavia, Italy
| | - Patrizia Morbini
- Department of Molecular Medicine, Pathology Unit, University of Pavia; IRCCS Foundation Policlinico San Matteo, 27100, Pavia, Italy
| | - Miriam Colombo
- NanoBioLab, Department of Biotechnology and Biosciences, University of Milano-Bicocca, 20100, Milano, Italy
| | - Davide Prosperi
- NanoBioLab, Department of Biotechnology and Biosciences, University of Milano-Bicocca, 20100, Milano, Italy.,Nanomedicine Laboratory, ICS Maugeri S.P.A., 27100, Pavia, Italy
| | - Simona Viglio
- Department of Molecular Medicine, Biochemistry Unit, University of Pavia, 27100, Pavia, Italy
| | - Davide Piloni
- Department of Internal Medicine, Section of Pneumology, University of Pavia, Pavia, Italy.,Department of Respiratory Diseases, IRCCS Policlinico San Matteo Foundation, Pavia, Italy
| | - Rosanna Di Paola
- Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of Messina, 981000, Messina, Italy
| | - Salvatore Cuzzocrea
- Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of Messina, 981000, Messina, Italy.,Department of Pharmacological and Physiological Science, Saint Louis University School of Medicine, Saint Louis, MO, USA
| | - Federica Meloni
- Department of Respiratory Diseases, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.,Department of Internal Medicine, Section of Pneumology, University of Pavia, 27100, Pavia, Italy
| |
Collapse
|
21
|
Gagliardi S, Morasso C, Stivaktakis P, Pandini C, Tinelli V, Tsatsakis A, Prosperi D, Hickey M, Corsi F, Cereda C. Curcumin Formulations and Trials: What's New in Neurological Diseases. Molecules 2020; 25:molecules25225389. [PMID: 33217959 PMCID: PMC7698610 DOI: 10.3390/molecules25225389] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2020] [Revised: 11/12/2020] [Accepted: 11/15/2020] [Indexed: 02/07/2023] Open
Abstract
Curcumin’s pharmacological properties and its possible benefits for neurological diseases and dementia have been much debated. In vitro experiments show that curcumin modulates several key physiological pathways of importance for neurology. However, in vivo studies have not always matched expectations. Thus, improved formulations of curcumin are emerging as powerful tools in overcoming the bioavailability and stability limitations of curcumin. New studies in animal models and recent double-blinded, placebo-controlled clinical trials using some of these new formulations are finally beginning to show that curcumin could be used for the treatment of cognitive decline. Ultimately, this work could ease the burden caused by a group of diseases that are becoming a global emergency because of the unprecedented growth in the number of people aged 65 and over worldwide. In this review, we discuss curcumin’s main mechanisms of action and also data from in vivo experiments on the effects of curcumin on cognitive decline.
Collapse
Affiliation(s)
- Stella Gagliardi
- Genomic and Post Genomic Unit, IRCCS Mondino Foundation, 27100 Pavia, Italy; (S.G.); (C.P.)
| | - Carlo Morasso
- Istituti Clinici Scientifici Maugeri IRCCS, 27100 Pavia, Italy; (C.M.); (V.T.); (D.P.); (F.C.)
| | | | - Cecilia Pandini
- Genomic and Post Genomic Unit, IRCCS Mondino Foundation, 27100 Pavia, Italy; (S.G.); (C.P.)
- Department of Biology and Biotechnology “L. Spallanzani”, University of Pavia, 27100 Pavia, Italy
| | - Veronica Tinelli
- Istituti Clinici Scientifici Maugeri IRCCS, 27100 Pavia, Italy; (C.M.); (V.T.); (D.P.); (F.C.)
| | - Aristides Tsatsakis
- Medical School, University of Crete, 70013 Heraklion, Greece; (P.S.); (A.T.)
| | - Davide Prosperi
- Istituti Clinici Scientifici Maugeri IRCCS, 27100 Pavia, Italy; (C.M.); (V.T.); (D.P.); (F.C.)
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, 20126 Milano, Italy
| | - Miriam Hickey
- Department of Pharmacology, Institute of Biomedicine and Translational Medicine, University of Tartu, 50411 Tartu, Estonia;
| | - Fabio Corsi
- Istituti Clinici Scientifici Maugeri IRCCS, 27100 Pavia, Italy; (C.M.); (V.T.); (D.P.); (F.C.)
- Department of Biomedical and Clinical Sciences “Luigi Sacco”, University of Milan, 20157 Milano, Italy
| | - Cristina Cereda
- Genomic and Post Genomic Unit, IRCCS Mondino Foundation, 27100 Pavia, Italy; (S.G.); (C.P.)
- Correspondence: ; Tel.: +39-0382380348
| |
Collapse
|
22
|
Truffi M, Sevieri M, Morelli L, Monieri M, Mazzucchelli S, Sorrentino L, Allevi R, Bonizzi A, Zerbi P, Marchini B, Longhi E, Sampietro GM, Colombo F, Prosperi D, Colombo M, Corsi F. Anti-MAdCAM-1-Conjugated Nanocarriers Delivering Quantum Dots Enable Specific Imaging of Inflammatory Bowel Disease. Int J Nanomedicine 2020; 15:8537-8552. [PMID: 33173291 PMCID: PMC7646444 DOI: 10.2147/ijn.s264513] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2020] [Accepted: 09/01/2020] [Indexed: 12/19/2022] Open
Abstract
Purpose Assessment of inflammatory bowel disease (IBD) currently relies on aspecific clinical signs of bowel inflammation. Specific imaging of the diseased bowel regions is still lacking. Here, we investigate mucosal addressin cell adhesion molecule 1 (MAdCAM-1) as a reliable and specific endothelial target for engineered nanoparticles delivering imaging agents to obtain an exact mapping of diseased bowel foci. Materials and Methods We generated a nanodevice composed of PLGA-PEG coupled with anti-MAdCAM-1 antibody half-chains and loaded with quantum dots (P@QD-MdC NPs). Bowel localization and systemic biodistribution of the nanoconjugate were analyzed upon injection in a murine model of chronic IBD obtained through repeated administration of dextran sulfate sodium salt. Specificity for diseased bowel regions was also assessed ex vivo in human specimens from patients with IBD. Potential for development as contrast agent in magnetic resonance imaging was assessed by preliminary study on animal model. Results Synthesized nanoparticles revealed good stability and monodispersity. Molecular targeting properties were analyzed in vitro in a cell culture model. Upon intravenous injection, P@QD-MdC NPs were localized in the bowel of colitic mice, with enhanced accumulation at 24 h post-injection compared to untargeted nanoparticles (p<0.05). Nanoparticles injection did not induce histologic lesions in non-target organs. Ex vivo exposure of human bowel specimens to P@QD-MdC NPs revealed specific recognition of the diseased regions vs uninvolved tracts (p<0.0001). After loading with appropriate contrast agent, the nanoparticles enabled localized contrast enhancement of bowel mucosa in the rectum of treated mice. Conclusion P@QD-MdC NPs efficiently detected bowel inflammation foci, accurately following the expression pattern of MAdCAM-1. Fine-tuning of this nanoconjugate with appropriate imaging agents offers a promising non-invasive tool for specific IBD diagnosis.
Collapse
Affiliation(s)
- Marta Truffi
- Nanomedicine and Molecular Imaging Laboratory, Istituti Clinici Scientifici Maugeri IRCCS, Pavia 27100, Italy
| | - Marta Sevieri
- Department of Biomedical and Clinical Sciences "Luigi Sacco, Università degli studi di Milano, Milano, 20157, Italy
| | - Lucia Morelli
- NanoBioLab, Department of Biotechnology and Biosciences, Università degli studi di Milano-Bicocca, Milano, 20126, Italy
| | - Matteo Monieri
- Department of Biomedical and Clinical Sciences "Luigi Sacco, Università degli studi di Milano, Milano, 20157, Italy
| | - Serena Mazzucchelli
- Department of Biomedical and Clinical Sciences "Luigi Sacco, Università degli studi di Milano, Milano, 20157, Italy
| | - Luca Sorrentino
- Department of Biomedical and Clinical Sciences "Luigi Sacco, Università degli studi di Milano, Milano, 20157, Italy
| | - Raffaele Allevi
- Department of Biomedical and Clinical Sciences "Luigi Sacco, Università degli studi di Milano, Milano, 20157, Italy
| | - Arianna Bonizzi
- Department of Biomedical and Clinical Sciences "Luigi Sacco, Università degli studi di Milano, Milano, 20157, Italy
| | - Pietro Zerbi
- Department of Biomedical and Clinical Sciences "Luigi Sacco, Università degli studi di Milano, Milano, 20157, Italy
| | - Beatrice Marchini
- Department of Biomedical and Clinical Sciences "Luigi Sacco, Università degli studi di Milano, Milano, 20157, Italy
| | - Erika Longhi
- Department of Biomedical and Clinical Sciences "Luigi Sacco, Università degli studi di Milano, Milano, 20157, Italy
| | - Gianluca Matteo Sampietro
- IBD Surgery Unit, ASST Fatebenefratelli Sacco - Ospedale "Luigi Sacco" Polo Universitario, Milano, 20157, Italy
| | - Francesco Colombo
- IBD Surgery Unit, ASST Fatebenefratelli Sacco - Ospedale "Luigi Sacco" Polo Universitario, Milano, 20157, Italy
| | - Davide Prosperi
- NanoBioLab, Department of Biotechnology and Biosciences, Università degli studi di Milano-Bicocca, Milano, 20126, Italy
| | - Miriam Colombo
- NanoBioLab, Department of Biotechnology and Biosciences, Università degli studi di Milano-Bicocca, Milano, 20126, Italy
| | - Fabio Corsi
- Department of Biomedical and Clinical Sciences "Luigi Sacco, Università degli studi di Milano, Milano, 20157, Italy.,Surgery Department, Breast Unit, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, 27100, Italy
| |
Collapse
|
23
|
Das P, Salvioni L, Malatesta M, Vurro F, Mannucci S, Gerosa M, Antonietta Rizzuto M, Tullio C, Degrassi A, Colombo M, Ferretti AM, Ponti A, Calderan L, Prosperi D. Colloidal polymer-coated Zn-doped iron oxide nanoparticles with high relaxivity and specific absorption rate for efficient magnetic resonance imaging and magnetic hyperthermia. J Colloid Interface Sci 2020; 579:186-194. [PMID: 32590159 DOI: 10.1016/j.jcis.2020.05.119] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2020] [Revised: 05/29/2020] [Accepted: 05/30/2020] [Indexed: 02/07/2023]
Abstract
Colloidally stable nanoparticles-based magnetic agents endowed with very high relaxivity and specific absorption rate are extremely desirable for efficient magnetic resonance imaging and magnetic hyperthermia, respectively. Here, we report a water dispersible magnetic agent consisting of zinc-doped superparamagnetic iron oxide nanoparticles (i.e., Zn-SPIONs) of 15 nm size with high saturation magnetization coated with an amphiphilic polymer for effective magnetic resonance imaging and magnetic hyperthermia of glioblastoma cells. These biocompatible polymer-coated Zn-SPIONs had 24 nm hydrodynamic diameter and exhibited high colloidal stability in various aqueous media, very high transverse relaxivity of 471 mM-1 s-1, and specific absorption rate up to 743.8 W g-1, which perform better than most iron oxide nanoparticles reported in the literature, including commercially available agents. Therefore, using these polymer-coated Zn-SPIONs even at low concentrations, T2-weighted magnetic resonance imaging and moderate magnetic hyperthermia of glioblastoma cells under clinically relevant magnetic field were successfully implemented. In addition, the results of this in vitro study suggest the superior potential of Zn-SPIONs as a theranostic nanosystem for brain cancer treatment, simultaneously acting as a contrast agent for magnetic resonance imaging and a heat mediator for localized magnetic hyperthermia.
Collapse
Affiliation(s)
- Pradip Das
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, piazza della Scienza 2, 20126 Milano, Italy; Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genova, Italy
| | - Lucia Salvioni
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, piazza della Scienza 2, 20126 Milano, Italy
| | - Manuela Malatesta
- Neurosciences, Biomedicine and Movement Dept., School of Medicine, University of Verona, Strada le grazie 8, 37134 Verona, Italy
| | - Federica Vurro
- Computer Sciences Dept., University of Verona, Strada le grazie 7, Verona, Italy
| | - Silvia Mannucci
- Neurosciences, Biomedicine and Movement Dept., School of Medicine, University of Verona, Strada le grazie 8, 37134 Verona, Italy
| | - Marco Gerosa
- Computer Sciences Dept., University of Verona, Strada le grazie 7, Verona, Italy
| | - Maria Antonietta Rizzuto
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, piazza della Scienza 2, 20126 Milano, Italy
| | - Chiara Tullio
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, piazza della Scienza 2, 20126 Milano, Italy
| | - Anna Degrassi
- Toxicology, Accelera S.R.L. - NMS Group S.p.A., Viale Pasteur 10, 20014 Nerviano, MI, Italy
| | - Miriam Colombo
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, piazza della Scienza 2, 20126 Milano, Italy.
| | - Anna M Ferretti
- Istituto di Scienze e Tecnologie Chimiche "Giulio Natta" (SCITEC), Consiglio Nazionale delle Ricerche, via G, Fantoli 16/15, 20138 Milano, Italy
| | - Alessandro Ponti
- Istituto di Scienze e Tecnologie Chimiche "Giulio Natta" (SCITEC), Consiglio Nazionale delle Ricerche, via G, Fantoli 16/15, 20138 Milano, Italy
| | - Laura Calderan
- Neurosciences, Biomedicine and Movement Dept., School of Medicine, University of Verona, Strada le grazie 8, 37134 Verona, Italy
| | - Davide Prosperi
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, piazza della Scienza 2, 20126 Milano, Italy; Nanomedicine Laboratory, ICS Maugeri S.p.A. SB, via S. Maugeri 10, 27100 Pavia, Italy.
| |
Collapse
|
24
|
Bellini M, Riva B, Tinelli V, Rizzuto MA, Salvioni L, Colombo M, Mingozzi F, Visioli A, Marongiu L, Frascotti G, Christodoulou MS, Passarella D, Prosperi D, Fiandra L. Engineered Ferritin Nanoparticles for the Bioluminescence Tracking of Nanodrug Delivery in Cancer. Small 2020; 16:e2001450. [PMID: 32856404 DOI: 10.1002/smll.202001450] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/05/2020] [Revised: 07/16/2020] [Indexed: 06/11/2023]
Abstract
The identification of a highly sensitive method to check the delivery of administered nanodrugs into the tumor cells is a crucial step of preclinical studies aimed to develop new nanoformulated cures, since it allows the real therapeutic potential of these devices to be forecast. In the present work, the ability of an H-ferritin (HFn) nanocage, already investigated as a powerful tool for cancer therapy thanks to its ability to actively interact with the transferrin receptor 1, to act as an efficient probe for the monitoring of nanodrug delivery to tumors is demonstrated. The final formulation is a bioluminescent nanoparticle, where the luciferin probe is conjugated on nanoparticle surface by means of a disulfide containing linker (Luc-linker@HFn) which is subjected to glutathione-induced cyclization in tumor cell cytoplasm. The prolonged imaging of luciferase+ tumor models, demonstrated by an in vitro and an in vivo approach, associated with the prolonged release of luciferin into cancer cells by disulfide bridge reduction, clearly indicates the high efficiency of Luc-linker@HFn for drug delivery to the tumor tissues.
Collapse
Affiliation(s)
- Michela Bellini
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, P.zza della Scienza 2, Milan, 20126, Italy
| | - Benedetta Riva
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, P.zza della Scienza 2, Milan, 20126, Italy
| | - Veronica Tinelli
- Nanomedicine laboratory, ICS Maugeri S.p.A. SB, via S. Maugeri 10, Pavia, 27100, Italy
| | - Maria Antonietta Rizzuto
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, P.zza della Scienza 2, Milan, 20126, Italy
| | - Lucia Salvioni
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, P.zza della Scienza 2, Milan, 20126, Italy
| | - Miriam Colombo
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, P.zza della Scienza 2, Milan, 20126, Italy
| | - Francesca Mingozzi
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, P.zza della Scienza 2, Milan, 20126, Italy
| | - Alberto Visioli
- STEMGEN Spa, c/o Department of Biotechnology and Biosciences, University of Milano-Bicocca, P.zza della Scienza 2, Milan, 20126, Italy
| | - Laura Marongiu
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, P.zza della Scienza 2, Milan, 20126, Italy
| | - Gianni Frascotti
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, P.zza della Scienza 2, Milan, 20126, Italy
| | | | - Daniele Passarella
- Department of Chemistry, University of Milan, via Golgi 19, Milan, 20133, Italy
| | - Davide Prosperi
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, P.zza della Scienza 2, Milan, 20126, Italy
- Nanomedicine laboratory, ICS Maugeri S.p.A. SB, via S. Maugeri 10, Pavia, 27100, Italy
| | - Luisa Fiandra
- Department of Earth and Environmental Sciences, University of Milano-Bicocca, P.zza della Scienza 1, Milan, 20126, Italy
| |
Collapse
|
25
|
Rotem R, Micale A, Rizzuto MA, Migliavacca M, Giustra M, Salvioni L, Tasin F, Prosperi D, Colombo M. Modeling the interaction of amphiphilic polymer nanoparticles with biomembranes to Guide rational design of drug delivery systems. Colloids Surf B Biointerfaces 2020; 196:111366. [PMID: 32992287 DOI: 10.1016/j.colsurfb.2020.111366] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2020] [Revised: 08/05/2020] [Accepted: 08/31/2020] [Indexed: 10/23/2022]
Abstract
Nanoparticle assisted drug delivery to the cytoplasm is limited by sequestration of nanoparticles in endosomes. Endosomal escape through polymer-induced membrane destabilization is one of a few well characterized mechanisms to overcome it. Aiming to utilize this method in vivo, it is necessary to understand how modulating the structural and chemical features of the polymer and the presence of proteins in biological fluids can affect this activity. Here, as a model for the endosomal membrane, we use the membrane of red blood cells to evaluate the membrane destabilization ability of a model amphiphilic polymer in the presence of blood plasma using a hemolysis assay. This allows determination of red blood cells membrane permeabilization through the quantification of hemoglobin leakage. Our results showed a strong inhibitory effect of plasma, and that hemolytic activity can be improved by chemical modification of the polymeric micelle, reducing its interaction with plasma proteins. Finally, a second mechanism of pH-induced direct diffusion is proposed and tested using an oil/water partitioning model. These results offer a body of knowledge to improve delivery of drugs across biological membranes using carefully designed polymeric nanocarriers.
Collapse
Affiliation(s)
- Rany Rotem
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, Piazza della Scienza 2, 20126, Milano, Italy
| | - Angelo Micale
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, Piazza della Scienza 2, 20126, Milano, Italy
| | - Maria Antonietta Rizzuto
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, Piazza della Scienza 2, 20126, Milano, Italy
| | - Martina Migliavacca
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, Piazza della Scienza 2, 20126, Milano, Italy
| | - Marco Giustra
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, Piazza della Scienza 2, 20126, Milano, Italy
| | - Lucia Salvioni
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, Piazza della Scienza 2, 20126, Milano, Italy
| | - Federico Tasin
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, Piazza della Scienza 2, 20126, Milano, Italy
| | - Davide Prosperi
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, Piazza della Scienza 2, 20126, Milano, Italy; Nanomedicine Laboratory, ICS Maugeri S.p.A. SB, via S. Maugeri 10, 27100, Pavia, Italy.
| | - Miriam Colombo
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, Piazza della Scienza 2, 20126, Milano, Italy.
| |
Collapse
|
26
|
Rinzivillo M, Prosperi D, Mazzuca F, Magi L, Iannicelli E, Pilozzi E, Franchi G, Silveri GG, Laghi A, Annibale B, Signore A, Panzuto F. 1185P [18F]FDG-PET/CT and long-term response to everolimus in advanced neuroendocrine neoplasia. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1398] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
27
|
Salvioni L, Zuppone S, Andreata F, Monieri M, Mazzucchelli S, Di Carlo C, Morelli L, Cordiglieri C, Donnici L, De Francesco R, Corsi F, Prosperi D, Vago R, Colombo M. Nanoparticle‐Mediated Suicide Gene Therapy for Triple Negative Breast Cancer Treatment. Adv Therap 2020. [DOI: 10.1002/adtp.202000007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Lucia Salvioni
- NanoBioLabDepartment of Biotechnology and BiosciencesUniversity of Milano‐Bicocca Piazza della Scienza 2 Milan 20126 Italy
| | - Stefania Zuppone
- Urologic Research InstituteDivision of Experimental OncologyIRCCS San Raffaele Scientific Institute via Olgettina 60 Milan 20132 Italy
| | - Francesco Andreata
- Nanomedicine LaboratoryDepartment of Biomedical and Clinical Sciences “L. Sacco”Università degli Studi di Milano via G. B. Grassi, 74 Milan 20157 Italy
| | - Matteo Monieri
- Nanomedicine LaboratoryDepartment of Biomedical and Clinical Sciences “L. Sacco”Università degli Studi di Milano via G. B. Grassi, 74 Milan 20157 Italy
| | - Serena Mazzucchelli
- Nanomedicine LaboratoryDepartment of Biomedical and Clinical Sciences “L. Sacco”Università degli Studi di Milano via G. B. Grassi, 74 Milan 20157 Italy
| | - Caterina Di Carlo
- NanoBioLabDepartment of Biotechnology and BiosciencesUniversity of Milano‐Bicocca Piazza della Scienza 2 Milan 20126 Italy
| | - Lucia Morelli
- NanoBioLabDepartment of Biotechnology and BiosciencesUniversity of Milano‐Bicocca Piazza della Scienza 2 Milan 20126 Italy
| | - Chiara Cordiglieri
- INGM – Istituto Nazionale di Genetica Molecolare “Romeo ed Enrica Invernizzi,” Via Francesco Sforza 35 Milan 20122 Italy
| | - Lorena Donnici
- INGM – Istituto Nazionale di Genetica Molecolare “Romeo ed Enrica Invernizzi,” Via Francesco Sforza 35 Milan 20122 Italy
| | - Raffaele De Francesco
- INGM – Istituto Nazionale di Genetica Molecolare “Romeo ed Enrica Invernizzi,” Via Francesco Sforza 35 Milan 20122 Italy
- Department of Pharmacological and Biomolecular Sciences via Balzaretti 9 Milano 20133 Italy
| | - Fabio Corsi
- Nanomedicine LaboratoryDepartment of Biomedical and Clinical Sciences “L. Sacco”Università degli Studi di Milano via G. B. Grassi, 74 Milan 20157 Italy
- Breast UnitSurgery DepartmentICS Maugeri IRCCS via S. Maugeri 10 Pavia 27100 Italy
| | - Davide Prosperi
- NanoBioLabDepartment of Biotechnology and BiosciencesUniversity of Milano‐Bicocca Piazza della Scienza 2 Milan 20126 Italy
- Breast UnitSurgery DepartmentICS Maugeri IRCCS via S. Maugeri 10 Pavia 27100 Italy
| | - Riccardo Vago
- Urologic Research InstituteDivision of Experimental OncologyIRCCS San Raffaele Scientific Institute via Olgettina 60 Milan 20132 Italy
- Università Vita‐Salute San Raffaele via Olgettina, 58 Milan 20132 Italy
| | - Miriam Colombo
- NanoBioLabDepartment of Biotechnology and BiosciencesUniversity of Milano‐Bicocca Piazza della Scienza 2 Milan 20126 Italy
| |
Collapse
|
28
|
Tira R, De Cecco E, Rigamonti V, Santambrogio C, Barracchia CG, Munari F, Romeo A, Legname G, Prosperi D, Grandori R, Assfalg M. Dynamic molecular exchange and conformational transitions of alpha-synuclein at the nano-bio interface. Int J Biol Macromol 2020; 154:206-216. [DOI: 10.1016/j.ijbiomac.2020.03.118] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2020] [Revised: 03/11/2020] [Accepted: 03/13/2020] [Indexed: 10/24/2022]
|
29
|
Benke D, Fries M, Specht M, Wortmann J, Pabst M, Gottschall T, Radulov I, Skokov K, Bevan AI, Prosperi D, Tudor CO, Afiuny P, Zakotnik M, Gutfleisch O. Magnetic Refrigeration with Recycled Permanent Magnets and Free Rare-Earth Magnetocaloric La-Fe-Si. Energy Technol (Weinh) 2020; 8:1901025. [PMID: 32728520 PMCID: PMC7380313 DOI: 10.1002/ente.201901025] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/27/2019] [Revised: 03/17/2020] [Indexed: 05/29/2023]
Abstract
Magnetic refrigeration is an upcoming technology that could be an alternative to the more than 100-year-old conventional gas-vapor compression cooling. Magnetic refrigeration might answer some of the global challenges linked with the increasing demands for readily available cooling in almost every region of the world and the global-warming potential of conventional refrigerants. Important issues to be solved are, for example, the required mass and the ecological footprint of the rare-earth permanent magnets and the magnetocaloric material, which are key parts of the magnetic cooling device. The majority of existing demonstrators use Nd-Fe-B permanent magnets, which account for more than 50% of the ecological footprint, and Gd, which is a critical raw material. This work shows a solution to these problems by demonstrating the world's first magnetocaloric demonstrator that uses recycled Nd-Fe-B magnets as the magnetic field source, and, as a Gd replacement material, La-Fe-Mn-Si for the magnetocaloric heat exchanger. These solutions show that it is possible to reduce the ecological footprint of magnetic cooling devices and provides magnetic cooling as a green solid-state technology that has the potential to satisfy the rapidly growing global demands.
Collapse
Affiliation(s)
| | | | | | | | - Marc Pabst
- Material ScienceTU Darmstadt64287DarmstadtGermany
| | | | | | | | - Alex Ivor Bevan
- Urban Mining Company1550 Clovis Barker Rd.San MarcosTX78666USA
| | - Davide Prosperi
- Urban Mining Company1550 Clovis Barker Rd.San MarcosTX78666USA
| | | | - Peter Afiuny
- Urban Mining Company1550 Clovis Barker Rd.San MarcosTX78666USA
| | - Miha Zakotnik
- Urban Mining Company1550 Clovis Barker Rd.San MarcosTX78666USA
| | - Oliver Gutfleisch
- Material ScienceTU Darmstadt64287DarmstadtGermany
- Institute for Resource Strategy and Materials CyclesFraunhofer IWKSHanauGermany
| |
Collapse
|
30
|
Affiliation(s)
- Davide Prosperi
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy.,Nanomedicine Laboratory, ICS Maugeri S.p.A. SB, via S. Maugeri, 10-27100 Pavia (PV), Italy
| |
Collapse
|
31
|
Salvioni L, Rizzuto MA, Bertolini JA, Pandolfi L, Colombo M, Prosperi D. Thirty Years of Cancer Nanomedicine: Success, Frustration, and Hope. Cancers (Basel) 2019; 11:E1855. [PMID: 31769416 PMCID: PMC6966668 DOI: 10.3390/cancers11121855] [Citation(s) in RCA: 106] [Impact Index Per Article: 21.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2019] [Revised: 11/21/2019] [Accepted: 11/22/2019] [Indexed: 02/07/2023] Open
Abstract
Starting with the enhanced permeability and retention (EPR) effect discovery, nanomedicine has gained a crucial role in cancer treatment. The advances in the field have led to the approval of nanodrugs with improved safety profile and still inspire the ongoing investigations. However, several restrictions, such as high manufacturing costs, technical challenges, and effectiveness below expectations, raised skeptical opinions within the scientific community about the clinical relevance of nanomedicine. In this review, we aim to give an overall vision of the current hurdles encountered by nanotherapeutics along with their design, development, and translation, and we offer a prospective view on possible strategies to overcome such limitations.
Collapse
Affiliation(s)
- Lucia Salvioni
- Department of Biotecnology and Bioscience, University of Milano-Bicocca, piazza della Scienza 2, 20126 Milano, Italy; (L.S.); (M.A.R.); (J.A.B.); (M.C.)
| | - Maria Antonietta Rizzuto
- Department of Biotecnology and Bioscience, University of Milano-Bicocca, piazza della Scienza 2, 20126 Milano, Italy; (L.S.); (M.A.R.); (J.A.B.); (M.C.)
| | - Jessica Armida Bertolini
- Department of Biotecnology and Bioscience, University of Milano-Bicocca, piazza della Scienza 2, 20126 Milano, Italy; (L.S.); (M.A.R.); (J.A.B.); (M.C.)
| | - Laura Pandolfi
- Unit of Respiratory Diseases, IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy;
| | - Miriam Colombo
- Department of Biotecnology and Bioscience, University of Milano-Bicocca, piazza della Scienza 2, 20126 Milano, Italy; (L.S.); (M.A.R.); (J.A.B.); (M.C.)
| | - Davide Prosperi
- Department of Biotecnology and Bioscience, University of Milano-Bicocca, piazza della Scienza 2, 20126 Milano, Italy; (L.S.); (M.A.R.); (J.A.B.); (M.C.)
- Nanomedicine Laboratory, ICS Maugeri, via S. Maugeri 10, 27100 Pavia, Italy
| |
Collapse
|
32
|
Meloni F, Di Paola R, Morbini P, Pandolfi L, Frangipane V, Gugliandolo E, Cova E, Colombo M, Prosperi D, Vitulo P, Ferrario G, Fusco R, Pacini C, Siracusa R, Cuzzocrea S. Efficacy of imatinib loaded-antiCD44 coated gold nanoparticles: a possible new therapeutic approach to BOS. Transplantation 2019. [DOI: 10.1183/13993003.congress-2019.pa3361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
33
|
Codullo V, Cova E, Pandolfi L, Breda S, Morosini M, Frangipane V, Malatesta M, Calderan L, Cagnone M, Pacini C, Cavagna L, Recalde H, Distler JHW, Giustra M, Prosperi D, Colombo M, Meloni F, Montecucco C. Imatinib-loaded gold nanoparticles inhibit proliferation of fibroblasts and macrophages from systemic sclerosis patients and ameliorate experimental bleomycin-induced lung fibrosis. J Control Release 2019; 310:198-208. [PMID: 31430501 DOI: 10.1016/j.jconrel.2019.08.015] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2019] [Revised: 08/14/2019] [Accepted: 08/16/2019] [Indexed: 12/19/2022]
Abstract
Interstitial lung involvement in Systemic Sclerosis (SSc-ILD) is a complication with high morbidity and mortality. Specifically, engineered gold nanoparticles (GNPs) are proposed as targeted delivery system increasing efficacy of drugs with antifibrotic effect, such as tyrosine kinases. We aimed to test in vitro and in vivo the activity of targeted Imatinib (Im)-loaded GNP on SSc-ILD patients derived cells and in experimental model of lung fibrosis. GNPs functionalized with anti-CD44 and loaded with Im (GNP-HCIm) were synthesized. Lung fibroblasts (LFs) and alveolar macrophages from bronchoalveolar lavage fluids of SSc-ILD patients were cultured in presence of nanoparticles. GNP-HCIm significantly inhibited proliferation and viability inducing apoptosis of LFs and effectively reduced IL-8 release, viability and M2 polarization in alveolar macrophages. Anti-fibrotic effect of tracheal instilled GNP-HCIm was evaluated on bleomycin lung fibrosis mouse model comparing effect with common route of Im administration. GNP-HCIm were able to reduce significantly lung fibrotic changes and collagen deposition. Finally, electron microscopy revealed the presence of GNPs inside alveolar macrophages. These data support the use of GNPs locally administered in the development of new therapeutic approaches to SSc-ILD.
Collapse
Affiliation(s)
- Veronica Codullo
- Rheumatology service, Cochin Hospital, 75014 Paris, France; Unit of Rheumatology, IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy
| | - Emanuela Cova
- Unit of Respiratory Diseases, IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy
| | - Laura Pandolfi
- Unit of Respiratory Diseases, IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy
| | - Silvia Breda
- Unit of Rheumatology, IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy
| | - Monica Morosini
- Unit of Respiratory Diseases, IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy
| | - Vanessa Frangipane
- Unit of Respiratory Diseases, IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy
| | - Manuela Malatesta
- Department of Neurosciences, Biomedicine and Movement sciences, University of Verona, 37100 Verona, Italy
| | - Laura Calderan
- Department of Neurosciences, Biomedicine and Movement sciences, University of Verona, 37100 Verona, Italy
| | - Maddalena Cagnone
- Department of Molecular Medicine, Biochemistry Unit, University of Pavia, 27100 Pavia, Italy
| | - Chiara Pacini
- Department of Biotechnology and Bioscience, University of Milano-Bicocca, 20100 Milan, Italy
| | - Lorenzo Cavagna
- Unit of Rheumatology, IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy; Department of Internal Medicine, University of Pavia, section of Rheumatology, 27100 Pavia, Italy
| | - Helios Recalde
- Unit of Respiratory Diseases, IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy
| | - Jörg H W Distler
- Department of Internal Medicine, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), University Hospital Erlangen, 91050 Erlangen, Germany
| | - Marco Giustra
- Department of Biotechnology and Bioscience, University of Milano-Bicocca, 20100 Milan, Italy
| | - Davide Prosperi
- Department of Biotechnology and Bioscience, University of Milano-Bicocca, 20100 Milan, Italy; Laboratory of Nanotechnology, ICS Maugeri, 27100 Pavia, Italy
| | - Miriam Colombo
- Department of Biotechnology and Bioscience, University of Milano-Bicocca, 20100 Milan, Italy.
| | - Federica Meloni
- Unit of Respiratory Diseases, IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy; Department of Internal Medicine, University of Pavia, Section of Pneumology, 27100 Pavia, Italy
| | - Carlomaurizio Montecucco
- Unit of Rheumatology, IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy; Department of Internal Medicine, University of Pavia, section of Rheumatology, 27100 Pavia, Italy; Rheumatology service, Cochin Hospital, 75014 Paris, France
| |
Collapse
|
34
|
Avvakumova S, Pandolfi L, Soprano E, Moretto L, Bellini M, Galbiati E, Rizzuto MA, Colombo M, Allevi R, Corsi F, Sánchez Iglesias A, Prosperi D. Does conjugation strategy matter? Cetuximab-conjugated gold nanocages for targeting triple-negative breast cancer cells. Nanoscale Adv 2019; 1:3626-3638. [PMID: 36133537 PMCID: PMC9419579 DOI: 10.1039/c9na00241c] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/12/2019] [Accepted: 07/22/2019] [Indexed: 06/01/2023]
Abstract
The efficient targeting of cancer cells depends on the success of obtaining the active targeting of overexpressed receptors. A very accurate design of nanoconjugates should be done via the selection of the conjugation strategy to achieve effective targeted nanoconjugates. Here, we present a detailed study of cetuximab-conjugated nonspherical gold nanocages for the active targeting of triple-negative breast cancer cells, including MDA-MB-231 and MDA-MB-468. A few different general strategies were selected for monoclonal antibody conjugation to the nanoparticle surface. By varying the bioconjugation conditions, including antibody orientation or the presence of a polymeric spacer or recombinant protein biolinker, we demonstrate the importance of a rational design of nanoconjugates. A quantitative study of gold content via ICP-AES allowed us to compare the effectiveness of cellular uptake as a function of the conjugation strategy and confirmed the active nature of nanoparticle internalization in cancer cells via epidermal growth factor receptor recognition, corroborating the importance of the rational design of nanomaterials for nanomedicine.
Collapse
Affiliation(s)
- S Avvakumova
- University of Milano-Bicocca, Department of Biotechnology and Bioscience Piazza della Scienza, 2 20126 Milano Italy
| | - L Pandolfi
- Clinica di Malattie dell'Apparato Respiratorio, IRCCS Fondazione Policlinico San Matteo Pavia Italy
| | - E Soprano
- University of Milano-Bicocca, Department of Biotechnology and Bioscience Piazza della Scienza, 2 20126 Milano Italy
| | - L Moretto
- University of Milano-Bicocca, Department of Biotechnology and Bioscience Piazza della Scienza, 2 20126 Milano Italy
| | - M Bellini
- University of Milano-Bicocca, Department of Biotechnology and Bioscience Piazza della Scienza, 2 20126 Milano Italy
| | - E Galbiati
- University of Milano-Bicocca, Department of Biotechnology and Bioscience Piazza della Scienza, 2 20126 Milano Italy
| | - M A Rizzuto
- University of Milano-Bicocca, Department of Biotechnology and Bioscience Piazza della Scienza, 2 20126 Milano Italy
| | - M Colombo
- University of Milano-Bicocca, Department of Biotechnology and Bioscience Piazza della Scienza, 2 20126 Milano Italy
| | - R Allevi
- Dipartimento di Scienze Biomediche e Cliniche "Luigi Sacco", Università di Milano via G.B. Grassi 74 20157 Milano Italy
| | - F Corsi
- Dipartimento di Scienze Biomediche e Cliniche "Luigi Sacco", Università di Milano via G.B. Grassi 74 20157 Milano Italy
- Surgery Department, Breast Unit, ICS Maugeri S.p.A. SB via S. Maugeri 10 Pavia Italy
- Nanomedicine Laboratory, ICS Maugeri S.p.A. SB via S. Maugeri 10 Pavia Italy
| | - A Sánchez Iglesias
- Bionanoplasmonics Laboratory, CICbiomaGUNE Paseo de Miramón 182 20014 Donostia-San Sebastián Spain
| | - D Prosperi
- University of Milano-Bicocca, Department of Biotechnology and Bioscience Piazza della Scienza, 2 20126 Milano Italy
- Nanomedicine Laboratory, ICS Maugeri S.p.A. SB via S. Maugeri 10 Pavia Italy
| |
Collapse
|
35
|
Rizzuto MA, Salvioni L, Rotem R, Colombo M, Zanoni I, Granucci F, Prosperi D. Are nanotechnological approaches the future of treating inflammatory diseases? Nanomedicine (Lond) 2019; 14:2379-2390. [PMID: 31414616 DOI: 10.2217/nnm-2019-0159] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
The current treatments for chronic inflammatory diseases cause severe side effects due to nonspecific drug accumulation. Nanotechnology opens the way to new therapeutic strategies that exploit the ability of immune cells, and especially of phagocytes, to internalize nanoparticles. The cellular uptake of nanoparticles requires specific interactions and is affected by the chemical and physical properties of the carriers. Therefore, optimizing these properties is crucial for designing nanodrugs for immunotherapy. In perspective, we discuss the nanoparticle-based approaches that have been proposed to induce tolerance in autoimmune disorders and lessen the symptoms of inflammatory diseases.
Collapse
Affiliation(s)
- Maria Antonietta Rizzuto
- Department of Biotechnology & Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milano, Italy
| | - Lucia Salvioni
- Department of Biotechnology & Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milano, Italy
| | - Rany Rotem
- Department of Biotechnology & Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milano, Italy
| | - Miriam Colombo
- Department of Biotechnology & Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milano, Italy
| | - Ivan Zanoni
- Department of Biotechnology & Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milano, Italy.,Harvard Medical School and Division of Gastroenterology, Boston Children's Hospital, Boston, MA, USA
| | - Francesca Granucci
- Department of Biotechnology & Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milano, Italy
| | - Davide Prosperi
- Department of Biotechnology & Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milano, Italy.,Nanomedicine Laboratory, Surgery Department, ICS Maugeri, via S. Maugeri 10, 27100 Pavia, Italy
| |
Collapse
|
36
|
Cox C, Castiello L, Mattei M, Santodonato L, D'agostino G, Muraro E, Martorelli D, Lapenta C, Di Napoli A, Di Landro F, Cangemi M, Pavan A, Castaldo P, Hohaus S, Donati S, Montefiore E, Berdini C, Borgioni S, Carlei D, Monque D, Ruco L, Prosperi D, Tafuri A, Spadaro F, Sestili P, Spada M, Dolcetti R, Santini S, Rozera C, Arico' E, Capone I, Belardelli F. INTRANODAL TREATMENT WITH IFNΑ-DENDRITIC CELLS AND RITUXIMAB INDUCES SYSTEMIC CLINICAL RESPONSE AND ENDOGENOUS VACCINATION AGAINST FOLLICULAR LYMPHOMA: FINAL RESULT OF A PHASE I STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.126_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- C. Cox
- Haematology; AOU Sant'Andrea, Rome, Italy & King's College Foundation Trust; London United Kingdom
| | - L. Castiello
- FaBioCell; Core Facilities, Istituto Superiore di Sanita'; Rome Italy
| | - M. Mattei
- Radiology; AOU Sant'Andrea; Rome Italy
| | - L. Santodonato
- FaBioCell; Core Facilities, Istituto Superiore di Sanita'; Rome Italy
| | - G. D'agostino
- FaBioCell; Core Facilities, Istituto Superiore di Sanita'; Rome Italy
| | - E. Muraro
- Oncology; Centro di Riferimento Oncologico di Aviano (CRO), IRCCS; Aviano Italy
| | - D. Martorelli
- Oncology; Centro di Riferimento Oncologico di Aviano (CRO), IRCCS; Aviano Italy
| | - C. Lapenta
- Department of Oncology and Molecular Medicine; Istituto Superiore di Sanita'; Rome Italy
| | - A. Di Napoli
- Department of Clinical and Molecular Medicine; AOU Sant'Andrea; Rome Italy
| | - F. Di Landro
- Institute of Hematology; Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli, IRCCS; Rome Italy
| | - M. Cangemi
- Oncology; Centro di Riferimento Oncologico di Aviano (CRO), IRCCS; Aviano Italy
| | - A. Pavan
- Department of Clinical and Molecular Medicine; AOU Sant'Andrea; Rome Italy
| | | | - S. Hohaus
- Institute of Hematology; Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli, IRCCS; Rome Italy
| | - S. Donati
- Department of Oncology and Molecular Medicine; Istituto Superiore di Sanita'; Rome Italy
| | - E. Montefiore
- FaBioCell; Core Facilities, Istituto Superiore di Sanita'; Rome Italy
| | | | | | - D. Carlei
- FaBioCell; Core Facilities, Istituto Superiore di Sanita'; Rome Italy
| | - D. Monque
- FaBioCell; Core Facilities, Istituto Superiore di Sanita'; Rome Italy
| | - L. Ruco
- Department of Clinical and Molecular Medicine; AOU Sant'Andrea; Rome Italy
| | - D. Prosperi
- Nuclear Medicine; AOU Sant'Andrea; Rome Italy
| | - A. Tafuri
- Department of Clinical and Molecular Medicine; AOU Sant'Andrea; Rome Italy
| | - F. Spadaro
- Department of Oncology and Molecular Medicine; Istituto Superiore di Sanita'; Rome Italy
| | - P. Sestili
- Department of Oncology and Molecular Medicine; Istituto Superiore di Sanita'; Rome Italy
| | - M. Spada
- FaBioCell; Core Facilities, Istituto Superiore di Sanita'; Rome Italy
| | - R. Dolcetti
- Diamantina Institute; Translational Research Institute, The University of Queensland; Brisbane Australia
| | - S. Santini
- Department of Oncology and Molecular Medicine; Istituto Superiore di Sanita'; Rome Italy
| | - C. Rozera
- FaBioCell; Core Facilities, Istituto Superiore di Sanita'; Rome Italy
| | - E. Arico'
- FaBioCell; Core Facilities, Istituto Superiore di Sanita'; Rome Italy
| | - I. Capone
- FaBioCell; Core Facilities, Istituto Superiore di Sanita'; Rome Italy
| | - F. Belardelli
- institute of Translational Pharmacology; CNR; Rome Italy
| |
Collapse
|
37
|
Meloni F, Paola RD, Morbini P, Pandolfi L, Frangipane V, Gugliandolo E, Cova E, Colombo M, Prosperi D, Vitulo P, Ferrario G, Fusco R, Pacini C, Siracusa R, Cuzzocrea S. Development of a New Local Therapeutic Approach for BOS: Efficacy of Imatinib Loaded -antiCD44 Coated Gold Nanoparticles In Vitro and In Vivo. J Heart Lung Transplant 2019. [DOI: 10.1016/j.healun.2019.01.330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
38
|
Affiliation(s)
- Davide Prosperi
- Universita di Milano-Bicocca Dipartimento di Biotecnologie e Bioscienze NanoBioLab Piazza della Scienza 2, 20126, Milano, Italy
| | - Miriam Colombo
- Universita di Milano-Bicocca Dipartimento di Biotecnologie e Bioscienze NanoBioLab Piazza della Scienza 2, 20126, Milano, Italy
| |
Collapse
|
39
|
Das P, Fatehbasharzad P, Colombo M, Fiandra L, Prosperi D. Multifunctional Magnetic Gold Nanomaterials for Cancer. Trends Biotechnol 2019; 37:995-1010. [PMID: 30862388 DOI: 10.1016/j.tibtech.2019.02.005] [Citation(s) in RCA: 38] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2018] [Revised: 02/14/2019] [Accepted: 02/15/2019] [Indexed: 12/15/2022]
Abstract
The integration of multiple imaging and therapeutic agents into a customizable nanoplatform for accurate identification and rapid prevention of cancer is attracting great attention. Among the available theranostic nanosystems, magnetic gold nanoparticles are particularly promising as they exhibit unique physicochemical properties that can support multiple functions, including cancer diagnosis by magnetic resonance imaging, X-ray computed tomography, Raman and photoacoustic imaging, drug delivery, and plasmonic photothermal and photodynamic therapies. This review gives an overview of recent advances in the fabrication of multifunctional gold nanohybrids with magnetic and optical properties and their successful demonstration in multimodal imaging and therapy of cancer. Concerns around toxicity of these nanomaterials are also discussed in view of an imminent transition to clinical practice.
Collapse
Affiliation(s)
- Pradip Das
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, Piazza della Scienza 2, 20126 Milano, Italy
| | - Parisa Fatehbasharzad
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, Piazza della Scienza 2, 20126 Milano, Italy; Dipartimento di Biotecnologie Molecolari e Scienze per la Salute, Università di Torino, Via Nizza 52, 10126 Torino, Italy
| | - Miriam Colombo
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, Piazza della Scienza 2, 20126 Milano, Italy
| | - Luisa Fiandra
- Dipartimento di Scienze dell'Ambiente e della Terra, Università di Milano-Bicocca, Piazza della Scienza 2, 20126 Milano, Italy.
| | - Davide Prosperi
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, Piazza della Scienza 2, 20126 Milano, Italy; Nanomedicine Laboratory, ICS Maugeri S.p.A. SB, via S. Maugeri 10, 27100 Pavia, Italy.
| |
Collapse
|
40
|
Mazzucchelli S, Andreata F, Bonizzi A, Monieri M, Bellini M, Longhi E, Ottria R, Sorrentino L, Truffi M, Prosperi D, Zerbi P, Corsi F. Abstract P1-20-04: Nanoformulation of doxorubicin inside H- ferritin nanocages allows a cardio-safe combined therapy with trastuzumab: De-escalating cardiotoxicity in HER2-positive breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p1-20-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: HER2+ breast cancer (BC) accounts for 20-25 % of BCs and it is characterized by high aggressiveness.1 Despite the anti-HER2 monoclonal antibody Trastuzumab (TZ) has improved BC clinical outcome, it could induce severe cardiac reversible dysfunction:2 HER2 signaling is also essential for growth and survival of myocardiocytes.3 Therefore, the concurrent use of TZ with other cardiotoxic drugs as doxorubicin (DOX) is discouraged.3 Both neoadjuvant and adjuvant clinical trials have challenged the notion that TZ should be administered with anthracyclines only sequentially,4 despite pre-clinical studies demonstrated the significant enhancement of efficacy by their coadministration.5-7 Nanomedicine answers to this clinical issue with HFn-DOX: a natural protein-based DOX nanoformulation with native tumor targeting capability that displays a self-triggered nuclear delivery of DOX improving antitumor efficacy and reducing both chemoresistance and cardiotoxicity.8
Methods: HER2+ BC bearing mice have been treated 5 times twice a week with placebo, HFn-DOX (1 mg/Kg, i.v.), TZ (5 mg/Kg, i.p.) and with the combination of them. Main end-point were cardiotoxicity and anticancer efficacy. Tumor size was measured by caliper, while antitumor activity and cardiotoxicity were characterized by ICH, immunofluorescence, cytofluorimetry, TEM, mass spectrometry and western blot on resections. Statistical analyses were conducted using two-tailed Student's t-test (P< 0.05)
Results: Although single treatments with HFn-DOX or TZ display a good capability to reduce tumor progression, their combination improves antitumor potential, affecting tumor size and angiogenesis. Since the main TZ activity is the induction of the Antibody-Dependent Cell mediated Cytotoxicity, we have assessed the effect of HFn-DOX on Tumor Infiltrating Lymphocytes (TIL), revealing that both TILs enumeration and TIL activity is unaffected by HFn-DOX. On the other hand, HFn-DOX increases the induction of apoptosis, suggesting that the reduction of the tumor size observed in mice treated with the combination of TZ and HFn-DOX is attributable to the coupling of these activity. Mitochondrial morphology has been checked for cardiotoxicity. A pathological increase in mitochondria area coupled with cristae depletion has been evidenced only in mice treated with TZ alone, confirming the overall safety of the HFn-DOX formulation. Interestingly, mice treated with the TZ and HFn-DOX did not display evidences of cardiac suffering. TZ quantification in tumor and heart revealed that the combination with HFn-DOX couples the increased TZ accumulation and penetration in tumor with TZ reduction in heart, resulting in the lack of cardiotoxicity.
Conclusions: Our results suggest that a combined therapy with HFn-DOX and TZ allows an enhanced anticancer activity and reduced cardiotoxicity, with potential translational implications on the treatment of HER2+ BC patients.
[1] Nat Rev Cancer 2009; 9:463; [2] Nat. Med. 2012; 18(11):1639; [3] Cancer treatments reviews 2009; 35:633; [4] The breast 2014; 23:317; [5] Cancer Res. 1998; 58(13):2825; [6] Lancet Oncol. 2011; 12(3):236; [7] Lancet 2010; 375(9712):377. [8] Oncotarget. 2017; 8:8383.
Citation Format: Mazzucchelli S, Andreata F, Bonizzi A, Monieri M, Bellini M, Longhi E, Ottria R, Sorrentino L, Truffi M, Prosperi D, Zerbi P, Corsi F. Nanoformulation of doxorubicin inside H- ferritin nanocages allows a cardio-safe combined therapy with trastuzumab: De-escalating cardiotoxicity in HER2-positive breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-20-04.
Collapse
Affiliation(s)
- S Mazzucchelli
- University of Milan, Department of Biomedical and Clinical Sciences "L. Sacco", Milan, Italy; University of Milan-Bicocca, Milan, Italy; ICS Maugeri Spa SB, Breast Unit, Pavia, Italy
| | - F Andreata
- University of Milan, Department of Biomedical and Clinical Sciences "L. Sacco", Milan, Italy; University of Milan-Bicocca, Milan, Italy; ICS Maugeri Spa SB, Breast Unit, Pavia, Italy
| | - A Bonizzi
- University of Milan, Department of Biomedical and Clinical Sciences "L. Sacco", Milan, Italy; University of Milan-Bicocca, Milan, Italy; ICS Maugeri Spa SB, Breast Unit, Pavia, Italy
| | - M Monieri
- University of Milan, Department of Biomedical and Clinical Sciences "L. Sacco", Milan, Italy; University of Milan-Bicocca, Milan, Italy; ICS Maugeri Spa SB, Breast Unit, Pavia, Italy
| | - M Bellini
- University of Milan, Department of Biomedical and Clinical Sciences "L. Sacco", Milan, Italy; University of Milan-Bicocca, Milan, Italy; ICS Maugeri Spa SB, Breast Unit, Pavia, Italy
| | - E Longhi
- University of Milan, Department of Biomedical and Clinical Sciences "L. Sacco", Milan, Italy; University of Milan-Bicocca, Milan, Italy; ICS Maugeri Spa SB, Breast Unit, Pavia, Italy
| | - R Ottria
- University of Milan, Department of Biomedical and Clinical Sciences "L. Sacco", Milan, Italy; University of Milan-Bicocca, Milan, Italy; ICS Maugeri Spa SB, Breast Unit, Pavia, Italy
| | - L Sorrentino
- University of Milan, Department of Biomedical and Clinical Sciences "L. Sacco", Milan, Italy; University of Milan-Bicocca, Milan, Italy; ICS Maugeri Spa SB, Breast Unit, Pavia, Italy
| | - M Truffi
- University of Milan, Department of Biomedical and Clinical Sciences "L. Sacco", Milan, Italy; University of Milan-Bicocca, Milan, Italy; ICS Maugeri Spa SB, Breast Unit, Pavia, Italy
| | - D Prosperi
- University of Milan, Department of Biomedical and Clinical Sciences "L. Sacco", Milan, Italy; University of Milan-Bicocca, Milan, Italy; ICS Maugeri Spa SB, Breast Unit, Pavia, Italy
| | - P Zerbi
- University of Milan, Department of Biomedical and Clinical Sciences "L. Sacco", Milan, Italy; University of Milan-Bicocca, Milan, Italy; ICS Maugeri Spa SB, Breast Unit, Pavia, Italy
| | - F Corsi
- University of Milan, Department of Biomedical and Clinical Sciences "L. Sacco", Milan, Italy; University of Milan-Bicocca, Milan, Italy; ICS Maugeri Spa SB, Breast Unit, Pavia, Italy
| |
Collapse
|
41
|
Corsi F, Andreata F, Truffi M, Sorrentino L, D'Addio F, Monieri M, Gambaro A, Bellini M, Prosperi D, Mazzucchelli S. Abstract P4-06-09: Withdrawn. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-06-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Citation Format: Corsi F, Andreata F, Truffi M, Sorrentino L, D'Addio F, Monieri M, Gambaro A, Bellini M, Prosperi D, Mazzucchelli S. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-06-09.
Collapse
Affiliation(s)
- F Corsi
- University of Milan, Milan, Italy; Breast Unit, ICS Maugeri S.p.A. SB, Pavia, Italy; Clinical Oncology Unit, ASST Fatebenefratelli-Sacco, L. Sacco Hospital, Milan, Italy; University of Milan-Bicocca, Milan, Italy
| | - F Andreata
- University of Milan, Milan, Italy; Breast Unit, ICS Maugeri S.p.A. SB, Pavia, Italy; Clinical Oncology Unit, ASST Fatebenefratelli-Sacco, L. Sacco Hospital, Milan, Italy; University of Milan-Bicocca, Milan, Italy
| | - M Truffi
- University of Milan, Milan, Italy; Breast Unit, ICS Maugeri S.p.A. SB, Pavia, Italy; Clinical Oncology Unit, ASST Fatebenefratelli-Sacco, L. Sacco Hospital, Milan, Italy; University of Milan-Bicocca, Milan, Italy
| | - L Sorrentino
- University of Milan, Milan, Italy; Breast Unit, ICS Maugeri S.p.A. SB, Pavia, Italy; Clinical Oncology Unit, ASST Fatebenefratelli-Sacco, L. Sacco Hospital, Milan, Italy; University of Milan-Bicocca, Milan, Italy
| | - F D'Addio
- University of Milan, Milan, Italy; Breast Unit, ICS Maugeri S.p.A. SB, Pavia, Italy; Clinical Oncology Unit, ASST Fatebenefratelli-Sacco, L. Sacco Hospital, Milan, Italy; University of Milan-Bicocca, Milan, Italy
| | - M Monieri
- University of Milan, Milan, Italy; Breast Unit, ICS Maugeri S.p.A. SB, Pavia, Italy; Clinical Oncology Unit, ASST Fatebenefratelli-Sacco, L. Sacco Hospital, Milan, Italy; University of Milan-Bicocca, Milan, Italy
| | - A Gambaro
- University of Milan, Milan, Italy; Breast Unit, ICS Maugeri S.p.A. SB, Pavia, Italy; Clinical Oncology Unit, ASST Fatebenefratelli-Sacco, L. Sacco Hospital, Milan, Italy; University of Milan-Bicocca, Milan, Italy
| | - M Bellini
- University of Milan, Milan, Italy; Breast Unit, ICS Maugeri S.p.A. SB, Pavia, Italy; Clinical Oncology Unit, ASST Fatebenefratelli-Sacco, L. Sacco Hospital, Milan, Italy; University of Milan-Bicocca, Milan, Italy
| | - D Prosperi
- University of Milan, Milan, Italy; Breast Unit, ICS Maugeri S.p.A. SB, Pavia, Italy; Clinical Oncology Unit, ASST Fatebenefratelli-Sacco, L. Sacco Hospital, Milan, Italy; University of Milan-Bicocca, Milan, Italy
| | - S Mazzucchelli
- University of Milan, Milan, Italy; Breast Unit, ICS Maugeri S.p.A. SB, Pavia, Italy; Clinical Oncology Unit, ASST Fatebenefratelli-Sacco, L. Sacco Hospital, Milan, Italy; University of Milan-Bicocca, Milan, Italy
| |
Collapse
|
42
|
Cova E, Pandolfi L, Colombo M, Frangipane V, Inghilleri S, Morosini M, Mrakic-Sposta S, Moretti S, Monti M, Pignochino Y, Benvenuti S, Prosperi D, Stella G, Morbini P, Meloni F. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study. Int J Nanomedicine 2019; 14:773-785. [PMID: 30774332 PMCID: PMC6361319 DOI: 10.2147/ijn.s186344] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
PURPOSE Malignant pleural mesothelioma (MPM) is an aggressive tumor characterized by poor prognosis. Its incidence is steadily increasing due to widespread asbestos exposure. There is still no effective therapy for MPM. Pemetrexed (Pe) is one of the few chemotherapeutic agents approved for advanced-stage disease, although the objective response to the drug is limited. The use of gold nanoparticles (GNPs) as a drug delivery system promises several advantages, including specific targeting of malignant cells, with increased intracellular drug accumulation and reduced systemic toxicity, and, in the case of MPM, direct treatment administration into the pleural space. This study aims at exploring CD146 as a potential MPM cell-specific target for engineered Pe-loaded GNPs and to assess their effectiveness in inhibiting MPM cell line growth. METHODS MPM cell lines and primary cultures obtained by pleural effusions from MPM patients were assayed for CD146 expression by flow cytometry. Internalization by MPM cell lines of fluorescent dye-marked GNPs decorated with a monoclonal anti CD146 coated GNPs (GNP-HC) was proven by confocal microscopy. The effects of anti CD146 coated GNPs loaded with Pe (GNP-HCPe) on MPM cell lines were evaluated by cell cycle (flow cytometry), viability (MTT test), clonogenic capacity (soft agar assay), ROS production (electric paramagnetic resonance), motility (wound healing assay), and apoptosis (flow cytometry). RESULTS GNP-HC were selectively uptaken by MPM cells within 1 hour. MPM cell lines were blocked in the S cell cycle phase in the presence of GNP-HCPe. Both cell viability and motility were significantly affected by nanoparticle treatment compared to Pe. Apoptotic rate and ROS production were significantly higher in the presence of nanoparticles. Clonogenic capacity was completely inhibited following nanoparticle internalization. CONCLUSION GNP-HCPe treatment displays in vitro antineoplastic action and is more effective than Pe alone in inhibiting MPM cell line malignant phenotype. The innovative use of specifically targeted GNPs opens the perspective of local intrapleural administration to avoid normal cell toxicity and enhance chemotherapy efficacy.
Collapse
Affiliation(s)
- Emanuela Cova
- Clinic of Lung Diseases, IRCCS Foundation Policlinico San Matteo, Pavia, Italy,
| | - Laura Pandolfi
- Clinic of Lung Diseases, IRCCS Foundation Policlinico San Matteo, Pavia, Italy,
| | - Miriam Colombo
- Deparment of Biotechnology and Bioscience, University of Milano - Bicocca, Milan, Italy,
| | - Vanessa Frangipane
- Clinic of Lung Diseases, IRCCS Foundation Policlinico San Matteo, Pavia, Italy,
| | - Simona Inghilleri
- Clinic of Lung Diseases, IRCCS Foundation Policlinico San Matteo, Pavia, Italy,
| | - Monica Morosini
- Clinic of Lung Diseases, IRCCS Foundation Policlinico San Matteo, Pavia, Italy,
| | - Simona Mrakic-Sposta
- National Council of Research, Institute of Bioimaging and Molecular Physiology, Segrate, Milan, Italy
| | - Sarah Moretti
- National Council of Research, Institute of Bioimaging and Molecular Physiology, Segrate, Milan, Italy
| | - Manuela Monti
- Laboratory of Biotechnology, Research Center of Rigenerative Medicine, IRCCS Foundation Policlinico San Matteo, Pavia, Italy
| | - Ymera Pignochino
- Experimental Clinical Molecular Oncology, IRCCS Candiolo Cancer Institute-FPO, Candiolo, Turin, Italy
| | - Silvia Benvenuti
- Experimental Clinical Molecular Oncology, IRCCS Candiolo Cancer Institute-FPO, Candiolo, Turin, Italy
| | - Davide Prosperi
- Deparment of Biotechnology and Bioscience, University of Milano - Bicocca, Milan, Italy,
- Laboratory of Nanomedicine, Clinical Institute of Maugeri, S.p.A., Pavia, Italy
| | - Giulia Stella
- Clinic of Lung Diseases, IRCCS Foundation Policlinico San Matteo, Pavia, Italy,
| | - Patrizia Morbini
- Department of Molecular Medicine, Pathology Unit, IRCCS Foundation Policlinico San Matteo, Pavia, Italy
| | - Federica Meloni
- Department of Internal Medicine, Pneumology Unit, University of Pavia, Pavia, Italy
| |
Collapse
|
43
|
Colombo M, Rizzuto MA, Pacini C, Pandolfi L, Bonizzi A, Truffi M, Monieri M, Catrambone F, Giustra M, Garbujo S, Fiandra L, Corsi F, Prosperi D, Mazzucchelli S. Half-Chain Cetuximab Nanoconjugates Allow Multitarget Therapy of Triple Negative Breast Cancer. Bioconjug Chem 2018; 29:3817-3832. [PMID: 30350574 DOI: 10.1021/acs.bioconjchem.8b00667] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
The use of therapeutic monoclonal antibodies (mAbs) has revolutionized cancer treatment. The conjugation of mAbs to nanoparticles has been broadly exploited to improve the targeting efficiency of drug nanocarriers taking advantage of high binding efficacy and target selectivity of antibodies for specific cell receptors. However, the therapeutic implications of nanoconjugation have been poorly considered. In this study, half-chain fragments of the anti-EGFR mAb cetuximab were conjugated to colloidal nanoparticles originating stable nanoconjugates that were investigated as surrogates of therapeutic mAbs in triple negative breast cancer (TNBC). Three TNBC cell lines were selected according to EGFR expression, which regulates activation of MAPK/ERK and PI3K/Akt pathways, and to distinctive molecular profiling including KRAS, PTEN, and BRCA1 mutations normally associated with diverse sensitivity to treatment with cetuximab. The molecular mechanisms of action of nanoconjugated half-chain mAb, including cell targeting, interference with downstream signaling pathways, proliferation, cell cycle, and apoptosis, along with triggering of ADCC response, were investigated in detail in sensitive and resistant TNBC cells. We found that half-chain mAb nanoconjugation was able to enhance the therapeutic efficacy and improve the target selectivity against sensitive, but unexpectedly also resistant, TNBC cells. Viability assays and signaling transduction modulation suggested a role of BRCA1 mutation in TNBC resistance to cetuximab alone, whereas its effect could be circumvented using half-chain cetuximab nanoconjugates, suggesting that nanoconjugation not only improved the antibody activity but also exerted different mechanisms of action. Our results provide robust evidence of the potential of half-chain antibody nanoconjugates in the treatment of TNBC, which could offer a new paradigm for therapeutic antibody administration, potentially allowing improved curative efficiency and reduced minimal effective dosages in both sensitive and resistant tumors.
Collapse
Affiliation(s)
- Miriam Colombo
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze , Università di Milano-Bicocca , Piazza della Scienza 2 , 20126 Milano , Italy
| | - Maria Antonietta Rizzuto
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze , Università di Milano-Bicocca , Piazza della Scienza 2 , 20126 Milano , Italy
| | - Chiara Pacini
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze , Università di Milano-Bicocca , Piazza della Scienza 2 , 20126 Milano , Italy
| | - Laura Pandolfi
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze , Università di Milano-Bicocca , Piazza della Scienza 2 , 20126 Milano , Italy
| | - Arianna Bonizzi
- Nanomedicine Laboratory , ICS Maugeri S.p.A. SB , via S. Maugeri 10 , 27100 Pavia , Italy
| | - Marta Truffi
- Department of Biomedical and Clinical Sciences "L. Sacco" , University of Milano , via G. B. Grassi 74 , 20157 Milano , Italy
| | - Matteo Monieri
- Department of Biomedical and Clinical Sciences "L. Sacco" , University of Milano , via G. B. Grassi 74 , 20157 Milano , Italy
| | - Francesco Catrambone
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze , Università di Milano-Bicocca , Piazza della Scienza 2 , 20126 Milano , Italy.,Department of Biomedical and Clinical Sciences "L. Sacco" , University of Milano , via G. B. Grassi 74 , 20157 Milano , Italy
| | - Marco Giustra
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze , Università di Milano-Bicocca , Piazza della Scienza 2 , 20126 Milano , Italy
| | - Stefania Garbujo
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze , Università di Milano-Bicocca , Piazza della Scienza 2 , 20126 Milano , Italy
| | - Luisa Fiandra
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze , Università di Milano-Bicocca , Piazza della Scienza 2 , 20126 Milano , Italy
| | - Fabio Corsi
- Department of Biomedical and Clinical Sciences "L. Sacco" , University of Milano , via G. B. Grassi 74 , 20157 Milano , Italy.,Nanomedicine Laboratory , ICS Maugeri S.p.A. SB , via S. Maugeri 10 , 27100 Pavia , Italy.,Surgery Department, Breast Unit , ICS Maugeri S.p.A. SB , via S. Maugeri 10 , 27100 Pavia , Italy
| | - Davide Prosperi
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze , Università di Milano-Bicocca , Piazza della Scienza 2 , 20126 Milano , Italy.,Nanomedicine Laboratory , ICS Maugeri S.p.A. SB , via S. Maugeri 10 , 27100 Pavia , Italy
| | - Serena Mazzucchelli
- Department of Biomedical and Clinical Sciences "L. Sacco" , University of Milano , via G. B. Grassi 74 , 20157 Milano , Italy
| |
Collapse
|
44
|
Das P, Colombo M, Prosperi D. Recent advances in magnetic fluid hyperthermia for cancer therapy. Colloids Surf B Biointerfaces 2018; 174:42-55. [PMID: 30428431 DOI: 10.1016/j.colsurfb.2018.10.051] [Citation(s) in RCA: 119] [Impact Index Per Article: 19.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2018] [Revised: 10/12/2018] [Accepted: 10/18/2018] [Indexed: 10/28/2022]
Abstract
Recently, magnetic fluid hyperthermia using biocompatible magnetic nanoparticles as heat mediators for cancer therapy has been extensively investigated due to its high efficiency and limited side effects. However, the development of more efficient heat nanomediators that exhibit very high specific absorption rate (SAR) value is essential for clinical application to overcome the several restrictions previously encountered due to the large quantity of nanomaterial required for effective treatment. In this review, we focus on the current progress in the development of magnetic nanoparticles based hyperthermia therapy as well as combined therapy harnessing hyperthermia with heat-mediated drug delivery for cancer treatment. We also address the fundamental principles of magnetic hyperthermia, basics of magnetism including the effect of several parameters on heating capacity, synthetic methods and nanoparticle surface chemistry needed to design and develop an ideal magnetic nanoparticle heat mediator suitable for clinical translation in cancer therapy.
Collapse
Affiliation(s)
- Pradip Das
- NanoBioLab, Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza, 20126, Milan, Italy
| | - Miriam Colombo
- NanoBioLab, Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza, 20126, Milan, Italy
| | - Davide Prosperi
- NanoBioLab, Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza, 20126, Milan, Italy.
| |
Collapse
|
45
|
Affiliation(s)
- Francesca Granucci
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy.
| | - Davide Prosperi
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy; Nanomedicine laboratory, ICS Maugeri S.p.A. SB, via S. Maugeri, 10-27100 Pavia (PV), Italy.
| |
Collapse
|
46
|
Galbiati E, Avvakumova S, La Rocca A, Pozzi M, Messali S, Magnaghi P, Colombo M, Prosperi D, Tortora P. A fast and straightforward procedure for vault nanoparticle purification and the characterization of its endocytic uptake. Biochim Biophys Acta Gen Subj 2018; 1862:2254-2260. [PMID: 30036602 DOI: 10.1016/j.bbagen.2018.07.018] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2018] [Revised: 07/12/2018] [Accepted: 07/17/2018] [Indexed: 02/03/2023]
Abstract
BACKGROUND Vaults are eukaryotic ribonucleoprotein particles composed of up 78 copies of the 97 kDa major vault protein that assembles into a barrel-like, "nanocapsule" enclosing poly(ADP-ribose) polymerase, telomerase-associated protein-1 and small untranslated RNAs. Overall, the molecular mass of vault particles amounts to about 13 MDa. Although it has been implicated in several cellular functions, its physiological roles remain poorly understood. Also, the possibility to exploit it as a nanovector for drug delivery is currently being explored in several laboratories. METHODS Using the baculovirus expression system, vaults were expressed and purified by a dialysis step using a 1 MDa molecular weight cutoff membrane and a subsequent size exclusion chromatography. Purity was assessed by SDS-PAGE, transmission electron microscopy and dynamic light scattering. Particle's endocytic uptake was monitored by flow cytometry and confocal microscopy. RESULTS The purification protocol here reported is far simpler and faster than those currently available and lead to the production of authentic vault. We then demonstrated its clathrin-mediated endocytic uptake by normal fibroblast and glioblastoma, but not carcinoma cell lines. In contrast, no significant caveolin-mediated endocytosis was detected. CONCLUSIONS These results provide the first evidence for an intrinsic propensity of the vault complex to undergo endocytic uptake cultured eukaryotic cells. GENERAL SIGNIFICANCE The newly developed purification procedure will greatly facilitate any investigation based on the use of the vault particle as a natural nanocarrier. Its clathrin-mediated endocytic uptake observed in normal and in some tumor cell lines sheds light on its physiological role.
Collapse
Affiliation(s)
- Elisabetta Galbiati
- Department of Biotechnologies and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, I-20126 Milano, Italy
| | - Svetlana Avvakumova
- Department of Biotechnologies and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, I-20126 Milano, Italy
| | - Alessandra La Rocca
- Department of Biotechnologies and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, I-20126 Milano, Italy
| | - Maria Pozzi
- Department of Biotechnologies and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, I-20126 Milano, Italy
| | - Silvia Messali
- Oncology, Nerviano Medical Sciences, Viale Pasteur 10, Milano, 20014, Nerviano, Italy
| | - Paola Magnaghi
- Oncology, Nerviano Medical Sciences, Viale Pasteur 10, Milano, 20014, Nerviano, Italy
| | - Miriam Colombo
- Department of Biotechnologies and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, I-20126 Milano, Italy
| | - Davide Prosperi
- Department of Biotechnologies and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, I-20126 Milano, Italy
| | - Paolo Tortora
- Department of Biotechnologies and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, I-20126 Milano, Italy.
| |
Collapse
|
47
|
Prosperi D. Preface: A New Era of Nanoimmunology. Curr Pharm Biotechnol 2018; 19:2-4. [DOI: 10.2174/138920101901180531113953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Davide Prosperi
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| |
Collapse
|
48
|
Fumagalli G, Giorgi G, Vágvölgyi M, Colombo E, Christodoulou MS, Collico V, Prosperi D, Dosio F, Hunyadi A, Montopoli M, Hyeraci M, Silvani A, Lesma G, Via LD, Passarella D. Heteronanoparticles by Self-Assembly of Ecdysteroid and Doxorubicin Conjugates To Overcome Cancer Resistance. ACS Med Chem Lett 2018; 9:468-471. [PMID: 29795761 PMCID: PMC5949839 DOI: 10.1021/acsmedchemlett.8b00078] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2018] [Accepted: 04/17/2018] [Indexed: 12/22/2022] Open
Abstract
Heteronanoparticles (H-NPs) consisting of conjugates characterized by a squalene tail linked to doxorubicin and ecdysteroid derivatives are presented. Biological evaluation on A2780ADR cell line confirms not only the maintenance of the activity of the parental drug but also the ability to overcome cancer resistance. The in vitro cell uptake was demonstrated, and the involvement of an endosomal-mediated pathway was suggested.
Collapse
Affiliation(s)
- Gaia Fumagalli
- Dipartimento di Chimica, Università degli Studi di Milano, Milano 20133, Italy
| | - Giulia Giorgi
- Dipartimento di Chimica, Università degli Studi di Milano, Milano 20133, Italy
| | - Máté Vágvölgyi
- Szegedi Tudomanyegyetem (SZTE), Institute of Pharmacognosy, University of Szeged, 6720 Szeged, Hungary
| | - Eleonora Colombo
- Dipartimento di Chimica, Università degli Studi di Milano, Milano 20133, Italy
| | - Michael S Christodoulou
- DISFARM, Sezione "A. Marchesini", Università degli Studi di Milano, Via Venezian 21, 20133 Milano, Italy
| | - Veronica Collico
- Dipartimento di Biotecnologie e Bioscienze, Università Milano Bicocca, P.zza della Scienza 2, 20126 Milano, Italy
| | - Davide Prosperi
- Dipartimento di Biotecnologie e Bioscienze, Università Milano Bicocca, P.zza della Scienza 2, 20126 Milano, Italy
| | - Franco Dosio
- Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, Torino 10125, Italy
| | - Attila Hunyadi
- Szegedi Tudomanyegyetem (SZTE), Institute of Pharmacognosy, University of Szeged, 6720 Szeged, Hungary
| | - Monica Montopoli
- Dipartimento di Scienze del Farmaco, Università degli Studi di Padova, Via F. Marzolo 5, 35131 Padova, Italy
| | - Mariafrancesca Hyeraci
- Dipartimento di Scienze del Farmaco, Università degli Studi di Padova, Via F. Marzolo 5, 35131 Padova, Italy
| | - Alessandra Silvani
- Dipartimento di Chimica, Università degli Studi di Milano, Milano 20133, Italy
| | - Giordano Lesma
- Dipartimento di Chimica, Università degli Studi di Milano, Milano 20133, Italy
| | - Lisa Dalla Via
- Dipartimento di Scienze del Farmaco, Università degli Studi di Padova, Via F. Marzolo 5, 35131 Padova, Italy
| | - Daniele Passarella
- Dipartimento di Chimica, Università degli Studi di Milano, Milano 20133, Italy
| |
Collapse
|
49
|
Truffi M, Colombo M, Sorrentino L, Pandolfi L, Mazzucchelli S, Pappalardo F, Pacini C, Allevi R, Bonizzi A, Corsi F, Prosperi D. Multivalent exposure of trastuzumab on iron oxide nanoparticles improves antitumor potential and reduces resistance in HER2-positive breast cancer cells. Sci Rep 2018; 8:6563. [PMID: 29700387 PMCID: PMC5920071 DOI: 10.1038/s41598-018-24968-x] [Citation(s) in RCA: 48] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2017] [Accepted: 04/09/2018] [Indexed: 01/03/2023] Open
Abstract
Targeted therapies have profoundly changed the clinical prospect in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. In particular, the anti-HER2 monoclonal antibody trastuzumab represents the gold standard for the treatment of HER2+ breast cancer patients. Its contribution in dampening cancer progression is mainly attributed to the antibody-dependent cell-mediated cytotoxicity (ADCC) rather than HER2 blockade. Here, multiple half chains of trastuzumab were conjugated onto magnetic iron oxide nanoparticles (MNP-HC) to develop target-specific and biologically active nanosystems to enhance anti-HER2 therapeutic potential. HER2 targeting was assessed in different human breast cancer cell lines, where nanoparticles triggered site-specific phosphorylation in the catalytic domain of the receptor and cellular uptake by endocytosis. MNP-HC induced remarkable antiproliferative effect in HER2+ breast cancer cells, exhibiting enhanced activity compared to free drug. Accordingly, nanoparticles induced p27kip1 expression and cell cycle arrest in G1 phase, without loosing capability to prime ADCC. Finally, MNP-HC affected viability of trastuzumab-resistant cells, suggesting interference with the resistance machinery. Our findings indicate that multiple arrangement of trastuzumab half chain on the nanoparticle surface enhances anticancer efficacy in HER2+ breast cancer cells. Powerful inhibition of HER2 signaling could promote responsiveness of resistant cells, thus suggesting ways for drug sensitization.
Collapse
Affiliation(s)
- Marta Truffi
- Department of Biomedical and Clinical Sciences "L. Sacco", University of Milano, via G. B. Grassi 74, 20157, Milano, Italy
| | - Miriam Colombo
- NanoBioLab, Department of Biotechnologies and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126, Milano, Italy
| | - Luca Sorrentino
- Department of Biomedical and Clinical Sciences "L. Sacco", University of Milano, via G. B. Grassi 74, 20157, Milano, Italy
| | - Laura Pandolfi
- NanoBioLab, Department of Biotechnologies and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126, Milano, Italy
| | - Serena Mazzucchelli
- Department of Biomedical and Clinical Sciences "L. Sacco", University of Milano, via G. B. Grassi 74, 20157, Milano, Italy
| | - Francesco Pappalardo
- NanoBioLab, Department of Biotechnologies and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126, Milano, Italy
| | - Chiara Pacini
- NanoBioLab, Department of Biotechnologies and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126, Milano, Italy
| | - Raffaele Allevi
- Department of Biomedical and Clinical Sciences "L. Sacco", University of Milano, via G. B. Grassi 74, 20157, Milano, Italy
| | - Arianna Bonizzi
- Department of Biomedical and Clinical Sciences "L. Sacco", University of Milano, via G. B. Grassi 74, 20157, Milano, Italy
| | - Fabio Corsi
- Department of Biomedical and Clinical Sciences "L. Sacco", University of Milano, via G. B. Grassi 74, 20157, Milano, Italy. .,Surgery Department, Breast Unit, ICS Maugeri S.p.A. SB, via S. Maugeri 10, 27100, Pavia, Italy. .,Nanomedicine laboratory, ICS Maugeri S.p.A. SB, via S. Maugeri 10, 27100, Pavia, Italy.
| | - Davide Prosperi
- NanoBioLab, Department of Biotechnologies and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126, Milano, Italy. .,Nanomedicine laboratory, ICS Maugeri S.p.A. SB, via S. Maugeri 10, 27100, Pavia, Italy.
| |
Collapse
|
50
|
Fumagalli G, Christodoulou MS, Riva B, Revuelta I, Marucci C, Collico V, Prosperi D, Riva S, Perdicchia D, Bassanini I, García-Argáez A, Via LD, Passarella D. Self-assembled 4-(1,2-diphenylbut-1-en-1-yl)aniline based nanoparticles: podophyllotoxin and aloin as building blocks. Org Biomol Chem 2018; 15:1106-1109. [PMID: 28093593 DOI: 10.1039/c6ob02591a] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The ability of 4-(1,2-diphenylbut-1-en-1-yl)aniline as a self-assembly inducer is reported. The conjugation of this moiety with aloin or podophyllotoxin resulted in spherical nanoparticles that were characterized by Dynamic Light Scattering (DLS), Transmission Electron Microscopy (TEM) and NanoSight technology. A preliminary biological evaluation on two cancer cell lines is reported.
Collapse
Affiliation(s)
- Gaia Fumagalli
- Dipartimento di Chimica, Università degli Studi di Milano, Via Golgi 19, 20133 Milano, Italy.
| | - Michael S Christodoulou
- Dipartimento di Chimica, Università degli Studi di Milano, Via Golgi 19, 20133 Milano, Italy.
| | - Benedetta Riva
- Dipartimento di Biotecnologie e Bioscienze - Università degli Studi di Milano Bicocca, Piazza della scienza 2, 20126 Milano, Italy
| | - Inigo Revuelta
- Dipartimento di Chimica, Università degli Studi di Milano, Via Golgi 19, 20133 Milano, Italy.
| | - Cristina Marucci
- Dipartimento di Chimica, Università degli Studi di Milano, Via Golgi 19, 20133 Milano, Italy.
| | - Veronica Collico
- Dipartimento di Biotecnologie e Bioscienze - Università degli Studi di Milano Bicocca, Piazza della scienza 2, 20126 Milano, Italy
| | - Davide Prosperi
- Dipartimento di Biotecnologie e Bioscienze - Università degli Studi di Milano Bicocca, Piazza della scienza 2, 20126 Milano, Italy
| | - Sergio Riva
- Istituto di Chimica del Riconoscimento Molecolare - C.N.R., Via Mario Bianco 9, 20131 Milano, Italy
| | - Dario Perdicchia
- Dipartimento di Chimica, Università degli Studi di Milano, Via Golgi 19, 20133 Milano, Italy.
| | - Ivan Bassanini
- Dipartimento di Chimica, Università degli Studi di Milano, Via Golgi 19, 20133 Milano, Italy. and Istituto di Chimica del Riconoscimento Molecolare - C.N.R., Via Mario Bianco 9, 20131 Milano, Italy
| | - Aida García-Argáez
- Dipartimento di Scienze del Farmaco - Università degli Studi di Padova, Via F. Marzolo 5, 35131 Padova, Italy and Fondazione per la Biologia e la Medicina della Rigenerazione T.E.S.-Tissue Engineering and Signalling Onlus, Via F. Marzolo, 13, 35131 Padova, Italy
| | - Lisa Dalla Via
- Dipartimento di Scienze del Farmaco - Università degli Studi di Padova, Via F. Marzolo 5, 35131 Padova, Italy
| | - Daniele Passarella
- Dipartimento di Chimica, Università degli Studi di Milano, Via Golgi 19, 20133 Milano, Italy.
| |
Collapse
|